On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize colorectal cancer (CRC) as a heterogeneous malignancy primarily manifesting as adenocarcinoma, originating from the glandular epithelium of the large intestine. It typically follows the adenoma-carcinoma sequence, driven by the accumulation of genetic mutations in the Wnt/β-catenin signaling pathway, or the serrated pathway characterized by BRAF mutations and CpG island methylator phenotype (CIMP).
- •Identify the three primary molecular pathways: Chromosomal Instability (CIN), which accounts for 85% of sporadic cases; Microsatellite Instability (MSI), resulting from deficient mismatch repair (dMMR) seen in or sporadic MLH1 silencing; and the CIMP pathway. These pathways dictate tumor behavior, prognosis, and sensitivity to modern immunotherapies.
- •Distinguish between anatomical subtypes, as right-sided (proximal) tumors often present with different molecular profiles and worse prognoses compared to left-sided (distal) tumors. Rectal cancer, defined as occurring within 15 cm of the anal verge, requires distinct management strategies due to the narrow pelvic anatomy and the necessity of preserving sphincter function.
- •Screen for high-risk populations, including those with (Ulcerative Colitis or Crohn’s), hereditary syndromes like (FAP), or a significant family history. Emerging risk factors include central obesity, maternal obesity (intergenerational risk), and specific microbial signatures such as Fusobacterium nucleatum and Clostridioides difficile.
- •Monitor the shifting epidemiology toward early-onset colorectal cancer (EOCRC). Patients diagnosed before age 50 often present with more advanced stages and distal lesions, necessitating a lower threshold for diagnostic workup in symptomatic young adults who might otherwise be misdiagnosed with benign conditions like .
Evaluation
- •Suspect colorectal cancer in any adult presenting with iron-deficiency anemia, unexplained weight loss, or persistent changes in bowel habits such as new-onset constipation or 'pencil-thin' stools. Right-sided lesions often present with occult bleeding and fatigue, while left-sided lesions are more likely to cause overt and obstructive symptoms.
- •Ask specifically about the duration of symptoms, as the clinical nadir typically occurs 2 to 4 months before presentation. Inquire about a family history of colorectal or endometrial cancers to screen for using the Amsterdam II or Bethesda criteria.
- •Examine the patient thoroughly, starting with a mandatory digital rectal examination (DRE) to assess for low-lying rectal masses, fixation to surrounding tissues, and sphincter tone. Perform abdominal palpation to check for masses, hepatomegaly (suggestive of liver metastases), or (suggestive of peritoneal carcinomatosis).
- •Order a high-quality as the gold standard for diagnosis. Utilize computer-aided detection (CADe) systems where available to maximize the adenoma detection rate (ADR). If colonoscopy is incomplete or contraindicated, consider Computed Tomographic Colonography (CTC) or colon capsule endoscopy.
- •Obtain a tissue biopsy for histopathological confirmation and universal molecular testing. Every new diagnosis must be tested for mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) via immunohistochemistry or for microsatellite instability (MSI) via PCR to guide immunotherapy and identify hereditary risks.
- •Perform systemic staging using contrast-enhanced CT of the chest, abdomen, and pelvis to identify distant metastases. For rectal cancer, obtain a high-resolution pelvic MRI to assess the circumferential resection margin (CRM), extramural venous invasion (EMVI), and the depth of invasion relative to the mesorectal fascia.
- •Measure baseline serum Carcinoembryonic Antigen (CEA) levels. While not useful for screening due to low sensitivity, an elevated baseline CEA is a prognostic marker and serves as a vital tool for monitoring recurrence following curative-intent treatment.
- •Evaluate nutritional and inflammatory status using indices like the Prognostic Nutritional Index (PNI) or the Systemic Immune-inflammation Index (SII). Low albumin and high neutrophil-to-lymphocyte ratios are independent predictors of poor surgical outcomes and reduced overall survival.
- •Rule out paraneoplastic syndromes in atypical cases. For example, Erythema gyratum repens (a 'wood-grain' skin rash) or the sudden appearance of multiple seborrheic keratoses (Leser-Trélat sign) may be the first clinical indication of an underlying colonic malignancy.
- •Consider genetic counseling and germline multigene panel testing (MGPT) for all patients diagnosed under age 50 or those with tumor testing suggestive of a hereditary syndrome, regardless of family history.
Management
- •Initiate a multimodal prehabilitation program 2–4 weeks prior to elective surgery. This should include structured aerobic and resistance exercise, nutritional optimization, and psychological support to improve physiological reserve and reduce postoperative complications.
- •Perform surgical resection as the primary curative modality for localized disease. For colon cancer, execute a (CME) with central vascular ligation. For rectal cancer, (TME) is the gold standard to ensure the removal of the intact mesorectal envelope.
- •Utilize minimally invasive platforms, such as robotic-assisted surgery, particularly for complex rectal dissections. Robotic surgery is associated with lower conversion rates to open surgery and better visualization in the narrow male pelvis compared to conventional laparoscopy.
- •Administer adjuvant chemotherapy for Stage III colon cancer to eradicate micrometastases. The standard regimen is mFOLFOX6 (Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², and 5-FU 2400 mg/m² infusion) for 3 to 6 months depending on risk stratification (IDEA trial criteria).
- •Optimize the timing of adjuvant therapy, especially in patients with lymph-vascular invasion (LVI). Initiating chemotherapy within 3.2 weeks of surgical resection is associated with significantly improved overall survival.
- •Implement Total Neoadjuvant Therapy (TNT) for locally advanced rectal cancer. This involves delivering both chemotherapy (e.g., FOLFOX) and chemoradiotherapy (50.4 Gy with concurrent capecitabine) prior to surgery to increase pathological complete response (pCR) rates and facilitate organ preservation.
- •Prescribe Pembrolizumab 200 mg IV every 3 weeks as the first-line standard of care for patients with microsatellite instability-high (MSI-H) or dMMR metastatic colorectal cancer, as established by the KEYNOTE-177 trial.
- •Select targeted agents for metastatic disease based on RAS and BRAF status. For RAS wild-type, left-sided tumors, use anti-EGFR therapy (Cetuximab or Panitumumab). For RAS-mutated or right-sided tumors, combine chemotherapy with anti-VEGF therapy (Bevacizumab 5 mg/kg).
- •Treat BRAF V600E-mutated metastatic disease with the combination of Encorafenib 300 mg daily plus Cetuximab, which has shown superior survival outcomes in the second-line setting compared to standard chemotherapy.
- •Monitor for treatment-related toxicities, such as oxaliplatin-induced . Consider duloxetine 30–60 mg daily for established neuropathy or non-invasive magnetic field therapy for persistent pain.
- •Manage high-output stomas (HOS) aggressively in the early postoperative period to prevent dehydration and electrolyte imbalances. Monitor stoma output daily; outputs exceeding 1500 mL/day require medical intervention with antimotility agents and oral rehydration solutions.
- •Refer patients with colorectal peritoneal metastases for evaluation of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with Mitomycin C 30 mg/m² at specialized centers.
- •Follow a rigorous surveillance protocol post-resection: CEA testing every 3–6 months, annual CT scans of the chest/abdomen/pelvis, and colonoscopy at 1 year, then every 3–5 years based on findings.
- •Incorporate liquid biopsy (ctDNA) monitoring where available to detect molecular residual disease (MRD). Post-surgical ctDNA positivity is a highly specific predictor of recurrence and may guide the intensification of adjuvant therapy.
- •Avoid routine follow-up colonoscopy immediately after uncomplicated unless 'alarm' symptoms (anemia, weight loss) are present or the patient is over age 50 and overdue for screening.
- •Refer all patients with suspected hereditary syndromes to a specialized genetics clinic for cascade testing of biological relatives to prevent future cancers in the family.
Board Review — High Yield
- •Apple core lesion — Classic radiographic appearance of a constricting colorectal carcinoma on barium enema.
- •Streptococcus gallolyticus (bovis) — Bacteremia or endocarditis with this organism is highly associated with underlying colorectal neoplasia; mandatory colonoscopy required.
- •Lynch Syndrome — Autosomal dominant germline mutation in MMR genes (MLH1, MSH2, MSH6, PMS2); associated with proximal colon cancer and endometrial cancer.
- •FAP (Familial Adenomatous Polyposis) — APC gene mutation on chromosome 5q; results in thousands of polyps and 100% cancer risk by age 40 if untreated.
- •CEA (Carcinoembryonic Antigen) — Tumor marker used for monitoring recurrence, not for screening; high preoperative levels correlate with poor prognosis.
- •Turcot Syndrome — Association of hereditary polyposis with CNS tumors (medulloblastoma or glioblastoma).
- •Gardner Syndrome — FAP variant with extra-colonic manifestations including osteomas, desmoid tumors, and sebaceous cysts.
- •Microsatellite Instability (MSI-H) — Predicts excellent response to PD-1 inhibitors (Pembrolizumab) but poor response to 5-FU monotherapy in Stage II.
Deep Dive — Evidence Details
Colorectal Cancer: Definition, Synonyms, and Classification
- ▸Colorectal cancer is defined as an epithelial malignancy of the colon or rectum, with Early-Onset CRC (EOCRC) specifically defined by a diagnosis before age 50 [6, 15].
- ▸The AJCC 9th edition proposal introduces Tumor Deposits (TDs) as an independent staging parameter to resolve survival outcome non-hierarchies found in the 8th edition [13].
- ▸Histological classification requires >50% extracellular mucin to define the Mucinous Adenocarcinoma (MAC) subtype [11].
Colorectal cancer (CRC) is a malignant neoplastic disease arising from the epithelial lining of the colon or rectum, most commonly manifesting as adenocarcinoma [15]D. It remains a leading cause of cancer-related morbidity and mortality globally, with specific subtypes like stage III disease carrying a substantial risk of recurrence even after curative resection [4][18]D.
Synonyms and Alternate Names
Also Called: Colon cancer, Rectal cancer, Colorectal adenocarcinoma, Bowel cancer, and Large intestine cancer.
Clinical Phases and Definitions
To standardize the clinical course and of CRC, the following phases and terms are defined:
- Prodromal/Pre-malignant: The asymptomatic period or the phase of non-specific symptoms (e.g., occult bleeding, change in bowel habits) prior to definitive diagnosis. This often involves the adenoma-carcinoma sequence or the development of carcinoma in situ (Tis) [7]D.
- Progressive: The phase characterized by active tumor growth and local invasion through the bowel wall layers (T1–T4) or lymphatic/systemic spread [5][13]D.
- Nadir: In the oncological context, this refers to the point of maximal reduction in tumor burden or tumor markers (e.g., CEA) following neoadjuvant therapy or surgical resection.
- Plateau: A period of stable disease during surveillance where no evidence of progression or recurrence is detected via imaging or biomarkers [8]D.
- Recovery: The post-therapeutic phase focused on surgical healing, restoration of bowel function, and monitoring for long-term complications like frailty, often assessed via the Skeletal Muscle Index (SMI) [4].
Anatomical and Histological Classification
CRC is primarily classified by its anatomical location and histological features, which significantly influence prognosis and treatment response [11].
Anatomical Location
Tumors are categorized based on their position relative to the splenic flexure:
- Right-sided (Proximal) Colon: Includes the cecum, ascending colon, and transverse colon. These often present with different molecular profiles compared to distal tumors [11].
- Left-sided (Distal) Colon: Includes the descending colon and sigmoid colon [11].
- Rectum: Defined as the terminal portion of the large intestine, approximately 15 cm from the anal verge. Accurate locoregional staging in rectal cancer (especially T1) requires high-resolution MRI or endoscopic ultrasound (EUS) [5].
Histological Variants
| Variant Name | Key Distinguishing Feature | Associated Markers/Biology |
|---|---|---|
| Adenocarcinoma (NOS) | Most common type; originates from glandular epithelium. | Standard driver mutations (APC, KRAS, TP53) [6]D. |
| Mucinous Adenocarcinoma (MAC) | Characterized by >50% extracellular mucin component [11]. | Associated with distinct recurrence patterns depending on location [11]. |
| Signet Ring Cell Carcinoma | Cells contain large amounts of mucin that push the nucleus to the periphery. | Highly aggressive with poor prognosis. |
| Early-Onset CRC (EOCRC) | Diagnosis before age 50 [6]D[15]D. | Increased chromosomal instability; MYC, RAD21, GNAS, and MAPK1 amplifications [6]D. |
| Globo-H High CRC | High expression of the Globo-H glycan target [18]D. | Associated with DUSP14 overactivation [18]D. |
TNM Staging and the AJCC 9th Edition Proposals
The American Joint Committee on Cancer (AJCC) 8th edition is the current standard, though the 9th edition has proposed critical updates to address survival paradoxes [13]D. In the 8th edition, Stage IIIA patients often showed better survival than Stage II patients, a discrepancy the 9th edition seeks to rectify by rebalancing T and N stages and incorporating Tumor Deposits (TDs) as an independent parameter [13]D.
Invasion Depth (T-Stage) Protocol
Step 1 → Endoscopic Evaluation: Identification of the lesion and initial morphology assessment. Step 2 → Invasion Depth Prediction: Distinguishing between superficial (Tis/T1a) and deeply invasive (T1b) lesions. This is increasingly assisted by Artificial Intelligence (AI) to avoid unnecessary radical surgery for superficial lesions [7]D. Step 3 → Locoregional Staging: For rectal lesions, MRI and EUS are used to determine the depth of submucosal invasion and nodal involvement [5].
Molecular and Immune Stratification
Modern classification extends beyond histology to include the immune microenvironment and systemic inflammatory status. Multiplex immunohistochemistry (mIHC) is used to profile immune markers such as CD3, CD8, CD45RO, PD-1, LAG-3, and Tim-3 in the tumor center and invasive margin to predict outcomes [14]D.
Furthermore, systemic indices provide indirect measures of the host-tumor interaction:
- Prognostic Nutritional Index (PNI): Calculated from serum albumin and total lymphocyte count; lower scores correlate with poor overall survival (OS) [1].
- Systemic Immune-inflammation Index (SII): Integrates neutrophil, lymphocyte, and platelet counts to reflect the inflammatory state [2].
- Albumin/Neutrophil-to-Lymphocyte Ratio (ANLR): A combined metric used to stratify progression-free survival (PFS) [9][10].
Recent microbiome research has also reclassified key pathogens; for instance, the link between the Fusobacterium nucleatum group and CRC is now known to be driven specifically by Fusobacterium animalis [12]D.
| Biomarker | Threshold/Value | Clinical Significance |
|---|---|---|
| FIT (f-Hb) | ≥10 ug/g | Threshold for urgent cancer referral in symptomatic patients [17]D. |
| EOCRC Age | <50 years | Defines early-onset disease with distinct molecular biology [6]D[15]D. |
| Mucinous Component | >50% | Histological requirement for MAC classification [11]. |
| Skeletal Muscle Index (SMI) | Variable | Imaging-based surrogate for frailty and recurrence risk [4]. |
Epidemiology and Risk Factors
- ▸Colorectal cancer is the second leading cause of cancer death globally, with a rising incidence in adults under age 50 (early-onset CRC).
- ▸Central obesity and persistent poverty are major modifiable and social determinants that significantly increase CRC risk and mortality.
- ▸Infectious agents, including *Clostridioides difficile* and viral coinfections (HPV, EBV), are increasingly recognized as potential contributors to colonic tumorigenesis.
Colorectal cancer (CRC) represents a significant global health burden, currently ranking as the third most common malignancy and the second leading cause of cancer-related deaths worldwide [27][33]D[43]D. In the United States, CRC accounts for approximately 9% of all cancer deaths [45]D. While historically considered a disease of older populations, the epidemiological landscape is shifting due to rising incidence in younger cohorts and the identification of novel environmental and microbial risk factors.
Global Incidence and Temporal Trends
The incidence of CRC varies significantly by geography and socioeconomic development. In regions like Brazil, it has become the most common cancer diagnosed in both men and women [34]D. Conversely, in China, while premature mortality from many cancers is being addressed, CRC remains a primary driver of the cancer burden [40]D.
A critical temporal trend is the rise of early-onset colorectal cancer (EOCRC), defined as CRC diagnosed in individuals under age 50 [26]. Although a Nordic study showed EOCRC proportions fluctuating (comprising 7% of cases in 1995–2005 and 4% in 2006–2022), the absolute number of young patients is increasing globally, prompting calls for earlier screening [26][46]D. This shift is partly attributed to the rising prevalence of obesity and changes in the gut microbiome [32]D[46]D.
Demographic Distribution
Sex: Males consistently exhibit higher incidence and mortality rates than females [48]D. This disparity may be linked to differences in anti-tumor T cell responses; evidence suggests females mount stronger T cell receptor (TCR) abundance and clonality, which may contribute to improved survival outcomes [48]D.
Socioeconomic Status: Individuals living in persistent poverty areas—defined as regions where at least 20% of the population has lived below the poverty line for 30 years—face significantly higher CRC mortality [45]D. This is mediated by reduced access to medical care, lower quality of treatment, and increased complications rather than just disease aggressiveness [45]D.
Modifiable Risk Factors
Obesity and Metabolic Health
Central obesity is a more potent predictor of CRC risk than body mass index (BMI) alone [44]D. Elevated waist circumference is strongly associated with increased population attributable fractions (PAFs) for CRC, as visceral fat promotes a pro-inflammatory state conducive to tumorigenesis [44]D. Furthermore, maternal obesity may exert intergenerational effects, increasing the risk of CRC in offspring through epigenetic reprogramming and the vertical transmission of a dysbiotic gut microbiota [32]D.
Microbiome and Infectious Agents
Emerging evidence links specific enteric bacteria and viruses to colonic oncogenesis:
- Clostridioides difficile: Test positivity for C. difficile is associated with an increased risk of incident CRC [37]D. Research indicates that C. difficile is enriched in tumor tissues compared to matched normal tissues, potentially promoting tumorigenesis via toxin B-induced inflammation [37]D[41]D.
- Viral Coinfections: While (HPV) is a known driver of , coinfections with (EBV) and Polyomaviruses (JCPyV and BKPyV) are frequently detected in colorectal and anal samples, suggesting a synergistic role in viral-mediated oncogenesis [34]D.
Non-Modifiable and Clinical Risk Factors
Age and Adenoma History: Risk increases sharply with age. In adults aged 75 or older, the presence of a prior adenoma significantly elevates the cumulative risk of CRC compared to those with a clean prior [47]D. The detection of Sessile Serrated Lesions (SSLs), particularly those with dysplasia, represents a high-risk precursor state; the prevalence of SSLs with dysplasia in fecal immunochemical test (FIT)-positive screenees is a critical metric for screening programs [50]D.
Genetic Predisposition: Conditions such as (FAP) carry a near-certain risk of CRC without intervention. In FAP patients, surveillance must also include the upper tract, as gastric polyposis can progress to dysplasia and carcinoma [39]D.
Risk Factor Summary Table
| Risk Factor | Association/Impact | Evidence Level |
|---|---|---|
| Central Obesity | Higher PAF than BMI; major driver of global burden [44]D | 5 |
| Persistent Poverty | Increased mortality (OR not specified, but significant) [45]D | 5 |
| C. difficile Infection | Associated with increased incident CRC risk [37]D | 5 |
| Male Sex | Higher incidence and mortality; weaker T cell response [48]D | 5 |
| Prior Adenoma (Age >75) | Increased cumulative CRC risk [47]D | 5 |
| Maternal Obesity | Increased intergenerational risk for offspring [32]D | 5 |
Screening Initiation Protocol for High-Risk Populations
Based on the rising incidence of EOCRC and the impact of metabolic health, clinicians should consider risk-adapted screening ages [46]D:
- Step 1: Assess BMI and Metabolic Profile. Identify patients with obesity (BMI ≥30 kg/m²) or central obesity.
- Step 2: Determine Risk-Adapted Start Date. In countries like the US and Germany, individuals with obesity may need to initiate screening several years earlier than the standard recommended age (often age 45 or 50) to achieve a similar risk profile to non-obese peers [46]D.
- Step 3: Evaluate Family and Clinical History. Incorporate history of FAP, prior adenomas, or chronic inflammatory conditions like Ulcerative Colitis [35]D[39]D[47]D.
Impact of Global Disruptions
The pandemic caused significant disruptions in CRC screening and diagnosis. Modeling suggests these disruptions will lead to long-term increases in CRC cases and healthcare costs, particularly exacerbating inequalities in under-screened socioeconomic groups [31]D.
| Factor | Clinical Significance | Reference |
|---|---|---|
| Male Sex | Higher incidence and mortality; potentially due to lower TCR clonality | [48]D |
| Central Obesity | Stronger predictor of risk than BMI; promotes pro-inflammatory TME | [44]D |
| C. difficile | Enrichment in tumor tissue; toxin B linked to tumorigenesis | [37]D[41]D |
| Persistent Poverty | Linked to higher mortality via reduced access and treatment quality | [45]D |
| Maternal Obesity | Increases CRC susceptibility in the next generation | [32]D |
Etiology and Triggering Factors
- ▸Hereditary syndromes like Lynch and FAP account for 5-10% of CRC cases, necessitating universal tumor testing for MMR deficiency.
- ▸The gut microbiome, specifically Fusobacterium nucleatum and colibactin-producing E. coli, acts as a primary driver of tumorigenesis and immune evasion.
- ▸Metabolic disruptions, including cholecystectomy-induced bile acid changes and maternal obesity, are emerging as significant non-genetic triggers.
Colorectal cancer (CRC) arises from a complex interplay of germline genetic mutations, chronic inflammatory states, and dysbiotic microbial interactions that drive the transition from normal epithelium to invasive carcinoma [57]D[64]D[73]D. While sporadic cases account for the majority of diagnoses, approximately 5-10% of all CRCs are attributable to pathogenic germline variants (PGVs) in high-penetrance genes [64]D. The pathogenesis is increasingly recognized as a multi-factorial process involving the "sterile tumor" paradigm shift, where intratumoral and gut microbiomes act as active "co-conspirators" rather than passive bystanders [55]D[65]D.
Hereditary and Genetic Predispositions
Hereditary colorectal cancer (HCRC) syndromes are the most well-defined etiological factors, characterized by specific genetic defects that accelerate the adenoma-carcinoma or serrated neoplasia pathways [58]D[64]D.
- (HNPCC): Caused by germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, or PMS2). This leads to microsatellite instability (MSI) and a high mutational burden [64]D[68]D. It accounts for approximately 3% of all CRC cases [64]D.
- (FAP): An autosomal dominant condition caused by mutations in the APC gene, leading to the development of hundreds to thousands of colorectal adenomas [52]. Even after restorative proctocolectomy (RPC), patients remain at risk for "pouch cancer," with an incidence of approximately 3.4% in long-term follow-up [70]C.
- MUTYH-Associated Polyposis (MAP): A recessive syndrome involving defects in base excision repair, predisposing individuals to multiple adenomas and CRC [64]D.
- Rare Syndromes: These include Peutz-Jeghers syndrome (STK11), (SMAD4, BMPR1A), and PTEN Hamartoma Tumor syndrome [64]D.
Microbial and Infectious Triggers
The gut microbiome is a critical determinant of carcinogenesis, influencing genomic stability, immune evasion, and the tumor microenvironment (TME) [51][73]D.
- Fusobacterium nucleatum: This oral pathobiont acts as an "architect of the immune microenvironment." It employs virulence factors Fap2 (which binds TIGIT to inhibit NK and T-cell function) and FadA (which binds E-cadherin to activate Wnt/β-catenin signaling) to promote colonization and suppress anti-tumor immunity [55]D.
- Genotoxigenic Bacteria: Strains of Escherichia coli (producing colibactin), Campylobacter jejuni, and Helicobacter pylori produce toxins that induce direct DNA damage and genomic instability [66]D. H. pylori infection, while primarily gastric, increases extra-gastric cancer risk through exosome-mediated communication and gut dysbiosis [54]D.
- Oral-Gut Translocation: Pathogens like Porphyromonas gingivalis can translocate from the oral cavity to the gut, disrupting microbial homeostasis and activating Th17-mediated inflammation [69]D.
- Oncogenic Viruses: Viruses such as JC polyomavirus (JCPyV), Epstein-Barr virus (EBV), and human papillomavirus (HPV) have been detected in CRC tissues, potentially interfering with cell cycle regulation and DNA repair [66]D.
Chronic Inflammation and Autoimmunity
Colitis-associated colorectal cancer (caCRC) represents a distinct clinical entity arising from long-standing (IBD) [57]D.
- IBD (Ulcerative Colitis and Crohn's Disease): Unlike sporadic CRC, caCRC follows an "inflammation-dysplasia-carcinoma" sequence. Chronic mucosal inflammation drives oxidative stress, leading to DNA damage and clonal expansion of mutated epithelial cells [57]D.
- Cystic Fibrosis (CF): Patients with CF have a significantly higher risk of early-onset CRC. The mechanism involves the underlying CFTR genetic defect, altered intestinal pH, and a distinct dysbiotic microbiome [56]D.
Metabolic and Lifestyle Factors
Metabolic dysfunction and dietary exposures are increasingly linked to the rise of early-onset CRC (EOCRC) [63]D.
- Obesity and Maternal Programming: Maternal obesity may increase CRC risk in offspring through epigenetic reprogramming, immune dysregulation, and the vertical transmission of a dysbiotic microbiome [32]D.
- Cholesterol and Bile Acid Metabolism: High levels of secondary bile acids (e.g., deoxycholic acid) act as carcinogens. disrupts the enterohepatic circulation, leading to continuous bile acid exposure in the colon and increasing the risk of right-sided CRC [59]D[61]D.
Protocol for Genetic Risk Stratification
Clinicians must systematically evaluate patients for hereditary risk to guide surveillance and surgical planning [64]D[68]D[72]D.
- Step 1: Clinical Screening: Evaluate all patients using the Amsterdam II criteria or Bethesda guidelines. Identify patients diagnosed at age <50 years [63]D[64]D.
- Step 2: Universal Tumor Testing: Perform immunohistochemistry (IHC) for MMR proteins (MLH1, MSH2, MSH6, PMS2) or PCR for microsatellite instability (MSI) on all resected CRC specimens [67]D[71]C.
- Step 3: Germline Multigene Panel Testing (MGPT): If tumor testing shows loss of MMR proteins (dMMR) or if clinical suspicion is high despite proficient MMR, proceed to NGS-based germline testing for PGVs [64]D[72]D.
- Step 4: Cascade Testing: If a PGV is identified, perform targeted testing for at-risk biological relatives [68]D.
| Cause | Category | Frequency | Associated Subtype | Key Mechanism |
|---|---|---|---|---|
| Lynch Syndrome | Hereditary | ~3% | MSI-High / dMMR | Germline MMR gene mutation [64]D[68]D |
| FAP | Hereditary | <1% | Adenomatous Polyposis | APC gene mutation; Wnt activation [52][70]C |
| F. nucleatum | Infectious | High (Sporadic) | Immunosuppressive TME | Fap2/FadA virulence factors [55]D |
| IBD | Inflammatory | Varies | caCRC | Chronic inflammation-dysplasia sequence [57]D |
| Cholecystectomy | Surgical/Metabolic | N/A | Right-sided CRC | Increased secondary bile acid exposure [61]D |
| Cystic Fibrosis | Genetic/Metabolic | Rare | Early-onset CRC | CFTR defect and dysbiosis [56]D |
Pathophysiology and Molecular Biology
- ▸CRC arises through three distinct molecular pathways: CIN (85%), MSI (15%), and CIMP, each requiring different therapeutic approaches.
- ▸Metastatic dissemination is characterized by a genomic bottleneck that enriches for SMAD4 loss and PTEN inactivation, facilitating organ-specific adaptation.
- ▸Early-onset CRC (<50 years) exhibits a unique molecular signature with increased copy number variations in MYC and RAD21, often presenting with more aggressive biology than late-onset disease.
Colorectal cancer (CRC) is a heterogeneous disease arising from the accumulation of genetic and epigenetic alterations that transform normal colonic epithelium into invasive adenocarcinoma. This transformation typically follows one of three primary molecular pathways: Chromosomal Instability (CIN), Microsatellite Instability (MSI), or the CpG Island Methylator Phenotype (CIMP) [83]D[84]D. Understanding these pathways is critical as they dictate tumor behavior, metastatic potential, and response to [67]D[85]D.
The Adenoma-Carcinoma Sequence and CIN
The Chromosomal Instability (CIN) pathway accounts for approximately 85% of sporadic CRC cases [85]D. It is characterized by numerical or structural chromosomal abnormalities, leading to high rates of loss of heterozygosity (LOH) and gene amplifications [6]D[84]D.
Step-by-Step Mechanism of CIN-driven Carcinogenesis:
- Initiation: Loss of the APC tumor suppressor gene (often via mutation or 5q deletion) leads to the stabilization of β-catenin, which translocates to the nucleus and activates Wnt-signaling target genes, promoting cellular proliferation [79]D[84]D.
- Promotion: Activating mutations in the KRAS or NRAS oncogenes (occurring in ~40% of cases) trigger the MAPK signaling pathway, bypassing normal growth factor requirements [77]D[84]D.
- Progression: Loss of the 18q region, involving SMAD4, impairs the TGF-β signaling pathway, which normally inhibits cell growth [76]D[84]D.
- Malignant Transformation: Inactivation of TP53 (the "guardian of the genome") prevents apoptosis and cell cycle arrest in response to DNA damage, allowing for the accumulation of further mutations [78]D[84]D.
Microsatellite Instability (MSI) and DNA Repair
MSI arises from a deficient mismatch repair (dMMR) system, which fails to correct errors (insertions or deletions) occurring during DNA replication in repetitive sequences known as microsatellites [72]D[84]D. This deficiency can be hereditary, as seen in (germline mutations in MLH1, MSH2, MSH6, or PMS2), or sporadic, typically due to epigenetic silencing of MLH1 [71]C[72]D.
Molecular Consequences of dMMR:
- Hypermutation: dMMR tumors exhibit a high tumor mutational burden (TMB), often exceeding 10-20 mutations/Mb [77]D[85]D.
- Neoantigen Production: The high frequency of frameshift mutations leads to the production of truncated, highly immunogenic proteins (neoantigens) [85]D.
- Immune Infiltration: These neoantigens recruit tumor-infiltrating lymphocytes (TILs), creating an "immune-hot" microenvironment that is highly sensitive to PD-1 blockade (e.g., 3 mg/kg) [80][82]C[96]D.
Epigenetic Regulation and the CIMP Pathway
DNA methylation is a key epigenetic modification where methyl groups are added to cytosine-phosphate-guanine (CpG) islands. In CRC, the CIMP phenotype is characterized by widespread hypermethylation of promoter regions, which silences tumor suppressor genes without altering the DNA sequence [83]D.
- Hypermethylation: Silencing of genes like MLH1 (leading to sporadic MSI) or p16 [83]D.
- Hypomethylation: Global DNA hypomethylation can lead to genomic instability and the activation of oncogenes [83]D.
- BRAF Association: CIMP is strongly associated with the BRAF V600E mutation, which is a hallmark of the serrated pathway of carcinogenesis [84]D.
The Metastatic Odyssey: Clonal Evolution
Metastasis is not a simple linear progression but an evolutionary journey. Multi-region sequencing suggests that metastatic seeding often occurs early, before clinical detection of the primary tumor [76]D.
The Metastatic Bottleneck: As cells disseminate, they undergo a "bottleneck" that reduces clonal diversity while enriching for specific traits [76]D:
- SMAD4 Loss: Strongly associated with the transition to disseminated disease and poor outcomes in lung and liver metastases [76]D[88]D.
- PTEN Inactivation: Promotes survival in the absence of cell-matrix attachment (anoikis resistance) [76]D[78]D.
- Organotropism: Metastases adapt to their target microenvironments. Liver metastases often show Wnt hyperactivation and TGF-β-driven immune suppression, while exhibit HER2 enrichment [76]D.
Microbial and Viral Pathogenesis
The gut microbiota and certain viruses act as extrinsic drivers of genomic instability and chronic inflammation [66]D.
- Genotoxigenic Bacteria: Strains of Escherichia coli (pks+), Campylobacter jejuni, and Helicobacter pylori produce toxins that directly induce DNA double-strand breaks [66]D.
- Oncogenic Viruses: Epstein-Barr virus (EBV), Human Papillomavirus (HPV), and JC Polyomavirus (JCPyV) have been detected in CRC tissues. These viruses can interfere with cell cycle regulation and DNA repair mechanisms [66]D.
- Microbial Metabolites: The gut microbiome produces metabolites and extracellular vesicles (EVs) that can either promote inflammation or enhance immune surveillance. For instance, Bifidobacterium catenulatum has been shown to boost anti-PD-1 efficacy by activating CD8+ T cells [53]D[89]D.
Early-Onset Colorectal Cancer (EO-CRC)
EO-CRC (diagnosed in patients <50 years) is biologically distinct from late-onset CRC (LO-CRC) [6]D[75]. It is characterized by more aggressive features and a higher prevalence of distal (left-sided) tumors [75].
Molecular Signature of EO-CRC:
- Increased Chromosomal Instability: Higher burden of copy number variations (CNVs) [6]D.
- Unique Amplifications: Frequent amplifications of MYC, RAD21, GNAS, and MAPK1 [6]D.
- Progenitor-like State: EO-CRC liver metastases often exhibit a progenitor-like transcriptional state and an "immune-cold" microenvironment with reduced myeloid and T-cell infiltration [6]D.
- Metabolic Stress: Early-life exposures and metabolic dysfunction (obesity) are significant contributors to the rising incidence of EO-CRC [63]D.
| Gene | Frequency | Pathway | Clinical Significance |
|---|---|---|---|
| APC | ~80% | Wnt/β-catenin | Initial gatekeeper mutation in the CIN pathway [84]D. |
| KRAS/NRAS | ~45% | MAPK/ERK | Predicts resistance to anti-EGFR therapies [77]D[84]D. |
| BRAF (V600E) | ~10% | Serrated/CIMP | Associated with poor prognosis and right-sided tumors [84]D. |
| TP53 | ~60% | Cell Cycle/Apoptosis | Late-stage mutation; facilitates genomic instability [84]D. |
| SMAD4 | ~15% | TGF-β | Marker for increased metastatic potential and poor survival [76]D[88]D. |
| MSI-H/dMMR | ~15% | DNA Repair | Primary biomarker for response to immune checkpoint inhibitors [85]D[91]D. |
| Feature | Early-Onset (EO-CRC) | Late-Onset (LO-CRC) |
|---|---|---|
| Age Threshold | < 50 years [75] | ≥ 50 years [75] |
| Primary Site | Predominantly Distal/Rectal [75] | More evenly distributed/Proximal |
| Genomic Profile | Higher CNV burden (MYC, RAD21) [6]D | Classic adenoma-carcinoma sequence |
| Immune State | Often 'Immune-Cold' in metastases [6]D | Variable; higher MSI-H in older females |
| Etiology | Metabolic stress, early-life exposures [63]D | Cumulative environmental/aging factors |
Clinical Features
- ▸Clinical presentation is primarily determined by tumor location, with right-sided lesions causing occult anemia and left-sided lesions causing obstruction.
- ▸High BMI (≥ 28 kg/m²) is a significant risk factor for early-onset colorectal cancer (age ≤ 50) and increases the technical difficulty of rectal cancer surgery.
- ▸Digital rectal examination and modern digital rectoscopy are essential for assessing rectal tumor characteristics and suitability for organ-preservation strategies.
The clinical presentation of (CRC) is highly heterogeneous, dictated primarily by the anatomical location of the primary tumor, the stage of disease at presentation, and patient-specific factors such as body mass index (BMI). While many patients are identified through screening while asymptomatic, those presenting clinically often exhibit a progression of symptoms over weeks to months. Understanding the physiological basis for these symptoms is essential for early detection and appropriate staging.
Presenting Symptoms
Patients typically present with a history of altered bowel habits, abdominal pain, or rectal bleeding. The timeline of progression is critical; symptoms often develop insidiously and reach a clinical nadir over 2 to 4 months before the patient seeks medical attention.
- Right-Sided (Proximal) Lesions: The ascending colon has a larger caliber and liquid fecal content. Consequently, tumors here often grow to a significant size before causing obstructive symptoms. Patients frequently present with symptoms of chronic occult blood loss, such as fatigue and dyspnea, leading to a diagnosis of iron-deficiency . Vague, dull abdominal pain may be the only localized symptom.
- Left-Sided (Distal) Lesions: The descending and sigmoid colon have a narrower lumen and more solid stool. Tumors in this region are more likely to cause obstructive symptoms, including a change in bowel habits (e.g., "pencil-thin" stools), colicky abdominal pain, and overt .
- Rectal Lesions: These often present with (a distressing sensation of incomplete evacuation), bright red blood per rectum, and occasionally mucus discharge.
Constitutional symptoms, particularly weight changes, are significant prognostic indicators. Significant weight loss is often observed in advanced stages, though preoperative weight loss interventions are sometimes utilized in patients with a BMI ≥ 28 kg/m² to reduce surgical morbidity [103]. Weight fluctuations are also common during adjuvant chemotherapy, where factors like age and chemotherapy regimen (e.g., oxaliplatin-containing) influence health-related quality of life [101].
Physical Examination Findings
A systematic physical examination is required to assess for local extension, metastatic spread, and the patient's physiological fitness for intervention.
- Abdominal Examination: Palpation may reveal a firm, non-tender mass, most commonly in the right lower quadrant (cecal cancer) or left lower quadrant (sigmoid cancer). The presence of hepatomegaly or a nodular liver edge suggests hepatic . may indicate peritoneal carcinomatosis.
- Rectal and Pelvic Examination: A digital rectal examination (DRE) is mandatory for any suspected CRC. It allows for the assessment of tumor distance from the anal verge, fixation to surrounding tissues, and the presence of palpable lymphadenopathy. In modern outpatient settings, digital rigid rectoscopy (e.g., LumenEye) provides high-resolution visualization and biopsy capability without the need for sedation, facilitating the "watch-and-wait" strategy for rectal organ preservation [110].
- Systemic and Autonomic Assessment: While not a primary feature of the cancer itself, autonomic and systemic stability must be assessed, particularly in older patients with . Intraoperative and postoperative blood pressure is critical; maintaining systolic blood pressure within ± 10% of baseline using agents like norepinephrine can reduce biomarkers of kidney injury during major abdominal resections [102]. Furthermore, patients receiving targeted therapies like must be monitored for treatment-induced hypertension (SBP/DBP ≥ 140/90 mmHg) and proteinuria [107].
Phenotypic Variants
The presentation of CRC varies significantly based on the patient's metabolic profile and the tumor's location. High BMI is a recognized risk factor, particularly for early-onset colorectal cancer (EOCRC), defined as diagnosis at age ≤ 50 years [106].
| Variant | Key Features | Frequency/Reasoning |
|---|---|---|
| Early-Onset CRC (EOCRC) | Occurs in patients ≤ 50 years; strongly associated with high BMI and often presents at more advanced stages [106]. | Increasing global incidence; requires high index of suspicion in younger symptomatic patients. |
| Right-Sided (Proximal) | Predominantly presents with occult bleeding, iron-deficiency anemia, and vague right-sided pain. | ~25-30% of cases; often diagnosed later due to subtle symptoms. |
| Left-Sided (Distal) | Presents with obstructive symptoms, changes in stool caliber, and overt hematochezia. | ~40-50% of cases; more likely to be detected early due to visible bleeding. |
| Low Rectal Cancer | Located within 5 cm of the dentate line; high surgical difficulty, especially in patients with BMI ≥ 28 kg/m² [109]. | ~15-20% of cases; requires specialized surgical approaches (e.g., LAR or APR). |
Red Flags
Certain clinical findings necessitate urgent diagnostic workup or surgical consultation to prevent catastrophic complications:
- Acute Bowel Obstruction: Characterized by obstipation, abdominal distension, and high-pitched or absent bowel sounds.
- Perforation: Sudden onset of severe, generalized abdominal pain with rebound tenderness and guarding.
- Severe Post-Procedural Pain: Following interventions like endoscopic submucosal dissection (ESD), moderate to severe pain occurs in 44.9-62.8% of patients [100]. Uncontrolled pain may indicate a complication or require advanced , such as bupivacaine liposome transversus abdominis plane (TAP) blocks [108] or lidocaine-based patient-controlled analgesia [104].
Atypical Presentations
Clinicians must remain vigilant for atypical presentations that may mimic other conditions. In younger patients, symptoms like rectal bleeding are frequently misattributed to , leading to delays in diagnosing EOCRC [106]. Additionally, long-term cancer survivors (surviving ≥ 5 years) may present with non-specific symptoms related to late-onset treatment effects or secondary malignancies, where lifestyle factors like smoking and physical activity levels significantly impact all-cause mortality [111][112].
| Variant | Key Features | Frequency/Reasoning |
|---|---|---|
| Early-Onset CRC | Age ≤ 50 years; associated with high BMI; often advanced at diagnosis [106]. | Increasing incidence; requires early investigation of symptoms. |
| Right-Sided | Occult bleeding, anemia, vague pain, larger mass at presentation. | ~30%; larger lumen allows for prolonged asymptomatic growth. |
| Left-Sided | Obstructive symptoms, pencil-thin stools, hematochezia. | ~45%; narrower lumen leads to earlier obstructive signs. |
| Low Rectal | Tenesmus, rectal bleeding; surgical difficulty increases with BMI ≥ 28 kg/m² [109]. | ~20%; proximity to anal sphincter complicates management. |
Diagnosis and Workup
- ▸Histopathological confirmation via colonoscopy remains the gold standard, with AI-based CADe systems significantly improving adenoma detection rates (ADR).
- ▸Universal testing for MSI/dMMR status is mandatory at diagnosis to identify candidates for immunotherapy and screen for Lynch syndrome.
- ▸The CA19-9/Albumin ratio and Red Blood Cell Distribution Width-to-Albumin Ratio (RAR) are emerging laboratory markers for prognosis and risk stratification.
The diagnosis of colorectal cancer (CRC) requires a multi-modal approach that integrates clinical suspicion, advanced endoscopic visualization, and precise histopathological and molecular characterization. Early detection is critical, as delays in diagnosis—such as those observed during the pandemic—significantly increase long-term healthcare costs and worsen health inequalities [31]D. Clinicians must maintain a high index of suspicion for early-onset CRC, particularly in patients under 50 years of age who present with hematochezia, abdominal pain, or changes in bowel habits, as primary care awareness of these symptoms remains a critical bottleneck in the diagnostic pathway [127]D.
Diagnostic Criteria
Formal diagnosis of CRC is established through histopathological confirmation of malignancy within a tissue specimen, typically obtained via endoscopic biopsy or surgical resection.
- Required Features: Histological evidence of adenocarcinoma (the most common subtype) or rare variants such as squamous cell carcinoma (SCC) [82]C.
- Supportive Features: Presence of iron-deficiency anemia [117]C, positive fecal immunochemical test (FIT) results [114], or paraneoplastic syndromes.
- Exclusion Criteria: Benign polyps (adenomas or sessile serrated lesions) without high-grade dysplasia or invasive components, and non-epithelial tumors such as lymphomas or mesenchymal tumors (GISTs), which require different protocols.
In rare instances, cutaneous manifestations serve as a sentinel for underlying CRC. Erythema gyratum repens (EGR), a pruritic eruption with a characteristic "wood-grain" pattern, is a highly specific paraneoplastic marker that often precedes the discovery of a colonic mass [117]C.
Laboratory Tests
Laboratory workup serves both diagnostic and prognostic functions, identifying systemic effects of the tumor and providing baseline markers for surveillance.
- (CBC): Often reveals microcytic anemia secondary to chronic occult blood loss, particularly in right-sided lesions [117]C.
- Red Blood Cell Distribution Width-to-Albumin Ratio (RAR): This emerging biomarker integrates inflammatory and nutritional status. Elevated RAR is significantly associated with a recent diagnosis of CRC [120]D.
- CA19-9/Albumin Ratio: In de novo metastatic CRC (mCRC), a high pretreatment CA19-9/Albumin ratio is a potent independent prognostic factor for poor overall survival [118].
- Mismatch Repair (MMR) and Microsatellite Instability (MSI) Testing: Essential for all new diagnoses. Patients with deficient MMR (dMMR) or MSI-High (MSI-H) status may show exceptional responses to PD-1 blockade (e.g., Pembrolizumab 200 mg every 3 weeks) [115][82]C.
- Extended Molecular Profiling: Testing for RAS and SMAD4 mutations is necessary for metastatic disease, as concurrent mutations in these genes predict poorer outcomes following interventions like thermal ablation for lung metastases [88]D.
Imaging
Imaging is the cornerstone of locoregional and systemic staging once a primary lesion is identified.
- Computed Tomography (CT): Contrast-enhanced CT of the chest, abdomen, and pelvis is the standard for detecting distant metastases and identifying the primary colonic mass [117]C.
- Magnetic Resonance Imaging (MRI): The gold standard for locoregional staging of rectal cancer. MRI is used to assess the circumferential resection margin (CRM) and extramural venous invasion (EMVI). In T1 rectal cancer, however, MRI and endoscopic ultrasound (EUS) show variable accuracy, often struggling to differentiate T1 from T2 stages [5].
- MRI Radiomics: Advanced radiomic models using baseline and delta-MRI features are being developed to predict response to neoadjuvant therapy and progression-free survival in patients with colorectal liver metastases (CRLM) [119]D.
Endoscopy and Advanced Detection
remains the definitive diagnostic tool. The effectiveness of colonoscopy is measured by the adenoma detection rate (ADR), which is the proportion of screening colonoscopies where at least one adenoma is found.
- Computer-Aided Detection (CADe): Artificial intelligence systems are now utilized to enhance ADR. Network meta-analyses of over 38,000 patients demonstrate that CADe significantly improves the detection of both adenomas and sessile serrated lesions (SSLs) [113]. Even in high-performance settings with expert endoscopists, CADe has been shown to further increase ADR, particularly in FIT-positive populations [114].
- Polypectomy and Anticoagulation: During diagnostic colonoscopy, the management of anticoagulation is vital. While traditional guidelines suggest interruption, emerging evidence suggests that maintaining anticoagulation during the resection of small lesions may be safe and reduces thromboembolic risks [116].
Diagnostic Algorithm
- Step 1: Clinical Suspicion & Screening: Identify patients with positive FIT, iron-deficiency anemia, or suggestive symptoms (e.g., EGR, weight loss, hematochezia) [117]C[120]D.
- Step 2: Endoscopic Evaluation: Perform high-quality colonoscopy, ideally utilizing CADe systems to maximize ADR [113][114].
- Step 3: Tissue Diagnosis: Biopsy of suspicious lesions for histopathology. Perform immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6, PMS2) [115][82]C.
- Step 4: Staging:
- Colon Cancer: CT Chest/Abdomen/Pelvis.
- Rectal Cancer: Pelvic MRI and/or EUS for T-staging [5].
- Step 5: Molecular Stratification: For advanced disease, assess RAS, BRAF, and SMAD4 status to guide targeted therapy and prognostic modeling [88]D[132]D.
| Test | Finding | Clinical Utility | Sensitivity/Specificity |
|---|---|---|---|
| Colonoscopy + CADe | Polyps, masses, SSLs | Primary diagnosis and prevention | High sensitivity for adenomas [113] |
| Pelvic MRI | T-stage, CRM involvement | Locoregional staging of rectal cancer | Variable for T1 vs T2 [5] |
| MSI/dMMR Testing | Loss of MMR proteins | Predicts response to PD-1 blockade | High specificity for Lynch/Immunotherapy [115] |
| CT Chest/Abd/Pelvis | Distant metastases | Systemic staging and mass identification | Standard for M-staging [117]C |
| RAR (RDW/Albumin) | Elevated ratio | Early detection and risk assessment | Associated with recent diagnosis [120]D |
Differential Diagnosis
- ▸Diverticulitis follow-up colonoscopy should be performed 4-6 weeks post-resolution, primarily in patients with complicated disease or persistent alarm symptoms.
- ▸IBD-associated neoplasia often presents as flat, indistinct lesions, requiring high-definition surveillance to distinguish from chronic inflammatory changes.
- ▸Metastatic CRC can rarely express TTF-1, potentially mimicking primary lung cancer; diagnosis requires CDX2 and SATB2 markers for confirmation.
The differential diagnosis of colorectal cancer (CRC) is broad, as its primary clinical manifestations—such as iron deficiency anemia (IDA), altered bowel habits, and rectal bleeding—overlap significantly with both benign and other malignant conditions [135][145]. Distinguishing CRC from inflammatory, infectious, and structural disorders is critical to ensure timely oncological intervention while avoiding unnecessary invasive procedures in low-risk patients [147]D.
Inflammatory Bowel Disease (IBD)
Inflammatory bowel diseases, including Ulcerative Colitis (UC) and (CD), represent the most significant diagnostic challenge due to their role as both a differential diagnosis and a precursor to malignancy [136]D[142]D. Chronic inflammation in IBD drives a multistep transition to neoplasia through genetic instability and epigenetic reprogramming [142]D.
- Clinical Presentation: Both IBD and CRC present with abdominal pain, weight loss, and hematochezia. However, IBD-associated colorectal neoplasia (UCAN) often presents as flat lesions with indistinct margins, making them harder to detect via standard endoscopy compared to sporadic CRC [136]D.
- Molecular Differentiation: In UC, the accumulation of cellular senescence markers, such as p16/p21 upregulation, telomere erosion, and loss of lamin B1, creates a senescence-associated secretory phenotype (SASP) that promotes barrier dysfunction and neoplasia [139]D. Furthermore, the presence of Fusobacterium nucleatum can complicate the picture, as it is implicated in both the inflammatory cascades of IBD and the promotion of CRC through β-catenin activation and immune evasion [141]D.
- Diagnostic Nuance: While regular surveillance is the gold standard for UC, Computed Tomographic Colonography (CTC) may be utilized to identify complications like strictures or fistulas that might mimic or mask a malignancy [144]D.
Diverticular Disease
Acute colonic often presents with symptoms that mimic obstructive left-sided CRC. Historically, routine follow-up colonoscopy was mandated for all patients after an episode of diverticulitis to exclude underlying malignancy [134][147]D.
- Follow-up Protocols: Current evidence suggests a more selective approach. Colonoscopy is strongly indicated 4-6 weeks after the resolution of acute diverticulitis if the patient has complicated disease, persistent alarm symptoms (e.g., weight loss, IDA), or imaging findings suggestive of neoplasia [134][147]D. For uncomplicated diverticulitis without alarm symptoms, the risk of missed CRC is low, and routine colonoscopy may lead to unnecessary complications [147]D.
- Alternative Imaging: Colon capsule endoscopy (CCE) has emerged as a diagnostic alternative to conventional colonoscopy for post-diverticulitis evaluation, offering a less invasive profile for patients concerned about physical discomfort [134].
Nonmalignant Gastrointestinal Disease and IDA
Iron deficiency anemia (IDA) is a hallmark of CRC but is frequently caused by nonmalignant pathologies. A systematic review indicates that while CRC must be excluded, clinicians must also consider a high prevalence of benign findings in IDA patients [135].
- Common Benign Mimics: These include , angiodysplasia, and erosive gastritis [135].
- and Polyps: Rectal bleeding is frequently attributed to hemorrhoids, but this can lead to a dangerous delay in CRC diagnosis, especially in older populations [145].
Laterally Spreading Tumors (LSTs)
LSTs are non-polypoid lesions (>10 mm) that spread circumferentially rather than vertically. They are easily missed during routine endoscopy due to their flat morphology [143]D.
- Subtypes: Non-granular (NG) LSTs have a significantly higher potential for malignant transformation compared to granular types [143]D.
- Diagnostic Importance: Identifying LSTs is crucial because they represent a distinct molecular pathway to CRC that does not follow the classic polyp-to-carcinoma sequence [143]D.
Other Malignancies and Metastatic Mimicry
Primary colorectal adenocarcinoma must be distinguished from other GI malignancies like lymphoma or gastrointestinal stromal tumors (GIST). Furthermore, metastatic lesions can occasionally present diagnostic pitfalls [146]C.
- TTF-1 Paradox: While Thyroid Transcription Factor-1 (TTF-1) is typically a marker for primary lung adenocarcinoma, rare cases of metastatic colorectal adenocarcinoma have shown aberrant TTF-1 nuclear positivity [146]C. In such cases, clinicians must rely on a broader immunohistochemical panel, including CK20 positivity, CDX2 expression, and SATB2 expression, to confirm a colorectal origin [146]C.
Diagnostic Algorithm for Differential Workup
- Step 1: Clinical Risk Stratification: Assess for "alarm symptoms" (weight loss, IDA, change in bowel habits) and family history [136]D[147]D.
- Step 2: Laboratory Evaluation: Confirm IDA and assess inflammatory markers (CRP/ESR) to differentiate between IBD and malignancy [135][142]D.
- Step 3: Primary Endoscopy: Perform colonoscopy with high-quality bowel preparation. The use of L-menthol (calcium channel blockade) as an antispasmodic during the procedure can improve visualization by reducing peristalsis [133].
- Step 4: Advanced Imaging: If colonoscopy is incomplete or contraindicated, utilize CT Colonography (CTC) to evaluate for extracolonic complications or proximal lesions [144]D.
- Step 5: Histopathological/Molecular Confirmation: Biopsy any suspicious lesions, paying close attention to flat LSTs or IBD-associated dysplasia [136]D[143]D.
| Condition | Key Clinical Features | Distinguishing Diagnostic Findings |
|---|---|---|
| Colorectal Cancer | IDA, weight loss, altered bowel habits | Endoscopic mass/ulcer; Biopsy confirmation [145] |
| Ulcerative Colitis | Bloody diarrhea, tenesmus, long duration | Continuous mucosal inflammation; p16/p21 upregulation [136]D[139]D |
| Diverticulitis | LLQ pain, fever, leukocytosis | CT findings of diverticula/fat stranding; resolution post-antibiotics [147]D |
| LST (Non-granular) | Often asymptomatic; found on screening | Flat morphology >10mm; high risk of submucosal invasion [143]D |
| Angiodysplasia | Chronic IDA in elderly | Cherry-red vascular lesions on endoscopy [135] |
| Modality | Primary Use in Differential | Limitations |
|---|---|---|
| Colonoscopy | Gold standard for direct visualization and biopsy | Invasive; risk of perforation in acute diverticulitis [134][147]D |
| CT Colonography | Evaluation of strictures, fistulas, or incomplete colonoscopy | Radiation exposure; cannot perform biopsy [144]D |
| Capsule Endoscopy | Patient-preferred alternative for post-diverticulitis | Limited availability; risk of capsule retention in strictures [134] |
| L-menthol (Adjunct) | Antispasmodic to improve endoscopic visualization | Temporary effect; requires local administration [133] |
Management: Surgical and Local Therapies
- ▸Complete Mesocolic Excision (CME) with Central Vascular Ligation (CVL) is the oncological standard for colon cancer, emphasizing intact mesenteric planes and apical lymph node clearance.
- ▸Robotic-assisted surgery (RAS) significantly reduces the rate of conversion to open surgery compared to laparoscopy, particularly in rectal cancer and obese patients.
- ▸The timing of adjuvant chemotherapy is critical; initiating treatment within 3.2 weeks of surgery is associated with better outcomes in patients with lymph-vascular invasion.
Surgical resection remains the primary curative modality for localized colorectal cancer (CRC). The evolution of surgical technique has shifted from simple segmental resection to oncologically precise dissections based on embryological planes, specifically (CME) for colon cancer and (TME) for rectal cancer [150][172]D. Modern emphasizes a multidisciplinary approach, integrating minimally invasive platforms and enhanced recovery protocols to optimize long-term oncological outcomes and perioperative safety [153][164]D.
Step 1: Preoperative Optimization and Risk Stratification
Before proceeding to resection, clinicians must assess physiological reserves and metabolic status. In patients aged ≥70 years, preoperative assessment using tools like the Flemish Triage Risk Screening Tool (fTRST) and the Age-Adjusted Charlson Comorbidity Index (ACCI) is essential, as these patients have higher 30-day readmission rates [154].
Correct electrolyte imbalances, particularly sodium. Abnormal preoperative sodium levels are significantly associated with increased mortality following colectomy [175]D. Furthermore, for patients with locally advanced rectal cancer (LARC), a pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) should be calculated; elevated NLR is a poor prognostic indicator for long-term survival following robotic-assisted resection [166]D.
Step 2: Surgical Resection for Colon Cancer (CME and CVL)
The standard of care for colon cancer is resection with Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) [150]. This technique involves the sharp dissection of the visceral fascia from the parietal fascia to remove an intact envelope of mesocolon containing the lymphovascular bundle [151].
- Identify Vascular Anatomy: For right-sided cancers, preoperative CTA mapping of the superior mesenteric artery (SMA) and Henle’s trunk is recommended to reduce vascular injury [174]D.
- Execute CVL: Ligate the feeding vessels at their origin (e.g., the ileocolic artery at the SMA) to ensure maximum lymph node yield [150].
- Extended Lymphadenectomy: In patients with BRAF-mutated stage I-III colon cancer, there is a higher risk of central mesocolic lymph node metastases, potentially justifying a more radical D3 dissection [160]D.
For descending colon cancer, preserving the inferior mesenteric artery (IMA) may be considered to improve early function recovery without compromising mid-term survival [163]D.
Step 3: Surgical Resection for Rectal Cancer (TME and Organ Preservation)
For rectal cancer, the surgical approach is dictated by the distance from the anal verge and the clinical stage.
- Total Mesorectal Excision (TME): This is the gold standard for mid-to-low rectal cancer, requiring the removal of the mesorectum as an intact unit [172]D. Quality assurance is vital; a "complete" TME grade is associated with better surgical margins and higher lymph node yields [172]D.
- Transanal Total Mesorectal Excision (TaTME): This "bottom-up" approach is indicated for mid and low rectal cancers (≤10 cm from the anal verge), particularly in male patients with a narrow pelvis or high BMI [148][161]D. While TaTME facilitates distal dissection, it has a significant learning curve [161]D.
- Transanal Minimally Invasive Surgery (TAMIS): A rectal-sparing technique suitable for benign lesions and very early-stage (cT1) rectal cancers [155].
- Lateral Lymph Node Dissection (LLND): In cases of LARC with suspected lateral node involvement, robotic-assisted BLLND can reduce blood loss compared to open surgery, though it increases operative time [168]D.
Step 4: Selection of Surgical Platform and Technique
Minimally invasive surgery (MIS) is the preferred standard. Robotic-assisted surgery (RAS) offers superior visualization and dexterity compared to conventional laparoscopic surgery (LACS) [153].
- Conversion Rates: RAS is associated with a significantly lower rate of conversion to open surgery compared to LACS, particularly in complex rectal dissections [153][156].
- Anastomotic Technique: For left-sided resections, the use of Powered Automated Firing Staplers (PAFS) may be preferred over manual staplers to potentially reduce the risk of anastomotic leaks [159].
- Intracorporeal Anastomosis (ICA): In robotic sigmoid colectomy, an ICA (using an IMV-first approach) may reduce incisional hernias and surgical site infections compared to extracorporeal techniques [158]C.
Step 5: Postoperative Management and Transition to Adjuvant Therapy
Implement Enhanced Recovery After Surgery (ERAS) protocols immediately. In patients undergoing simultaneous colorectal resection and hepatectomy for liver metastases, ERAS significantly reduces hospital stay and costs without increasing complications [164]D.
Timing of Adjuvant Chemotherapy: For colon cancer, the interval between surgery and chemotherapy is critical. In patients with lymph-vascular invasion (LVI), initiating chemotherapy within a 3.2-week threshold is associated with improved overall survival [128]D. For stage III dMMR colon cancer, the addition of Atezolizumab (1200 mg IV) to adjuvant mFOLFOX6 is currently under investigation to improve disease-free survival [149].
Drug Comparison Table: Perioperative and Adjuvant Agents
| Drug | Dose | Route | Indication | Key ADR | Evidence Level |
|---|---|---|---|---|---|
| FOLFOXIRI | Irinotecan 150 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2400 mg/m² | IV | Neoadjuvant for high-risk LARC [152] | Neutropenia, Diarrhea | 2b |
| Bevacizumab | 5 mg/kg | IV | Combined with neoadjuvant FOLFOXIRI [152] | , Bleeding | 2b |
| Atezolizumab | 1200 mg | IV | Adjuvant for Stage III dMMR Colon Cancer [149] | Immune-related AEs | 1b |
| mFOLFOX6 | Oxaliplatin 85 mg/m², Leucovorin 400 mg/m², 5-FU 400 mg/m² bolus + 2400 mg/m² | IV | Standard adjuvant for Stage III [149] | Neuropathy, Cytopenia | 1b |
Treatment Failure and Escalation Protocol
If standard surgical approaches fail to achieve oncological clearance or if complications arise:
- Incomplete TME Grade: If pathology reports an "incomplete" or "near-complete" specimen, multidisciplinary review is required to consider intensified adjuvant radiation or closer surveillance [172]D.
- (AL): In high-risk low rectal resections, a Delayed Coloanal Anastomosis (DCAA) may be used as an alternative to immediate anastomosis with diverting ileostomy to mitigate the impact of AL [129]D.
- Unplanned ICU Admission: Approximately 5.6% of elective colon resections require unplanned ICU admission; risk factors include advanced age and cardiovascular comorbidities [165]D.
What NOT to Do
- Do NOT delay adjuvant chemotherapy beyond 3.2 weeks in patients with high-risk features like LVI, as delays are linked to decreased survival [128]D.
- Do NOT perform upfront TME in early-stage rectal cancer without assessing for adverse pathological features (e.g., pT4 or R1 resection), which occur in approximately 19% of cases and may necessitate salvage therapy [171]D.
- Do NOT assume robotic surgery is faster; while it reduces blood loss and conversion, it consistently results in longer operative times than laparoscopic or open approaches [153][168]D.
| Feature | Laparoscopic (LACS) | Robotic (RAS) | Transanal (TaTME) |
|---|---|---|---|
| Conversion to Open | Higher [153] | Lower [156] | Low (in experienced hands) [148] |
| Operative Time | Shorter [156] | Longer [168]D | Long (Learning curve) [161]D |
| Visualization | 2D/Limited | 3D/High-definition [153] | Direct distal access [148] |
| Best For | Standard colon cancer | Rectal cancer, High BMI [167]D | Low rectal cancer [148] |
Management: Systemic and Radiation Therapy
- ▸Molecular profiling for RAS, BRAF V600E, and MMR status is mandatory to guide targeted and immunotherapy selection.
- ▸Adjuvant chemotherapy should ideally be initiated within 3.2 weeks in patients with lymph-vascular invasion to optimize survival outcomes.
- ▸The combination of encorafenib and cetuximab is the standard of care for BRAF V600E-mutant metastatic colorectal cancer following first-line failure.
The of colorectal cancer (CRC) has evolved into a precision-medicine paradigm where treatment selection is dictated by molecular profiling, including RAS, BRAF V600E, and mismatch repair (MMR) status [185]D[194]D. Systemic therapy aims to eradicate micrometastatic disease in the adjuvant setting and provide durable disease control in the metastatic phase. For rectal cancer, neoadjuvant strategies are prioritized to achieve local control and facilitate sphincter preservation [176][132]D.
Step 1: Molecular Profiling and Risk Stratification
Before initiating therapy, clinicians must determine the tumor's molecular signature. Mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) status is the primary biomarker for immunotherapy sensitivity [149][82]C. Conversely, pMMR/MSS tumors are considered "immunologically cold" due to an immunosuppressive tumor microenvironment (TME) often mediated by Fusobacterium nucleatum and myeloid-derived suppressor cells [55]D[191]D. For metastatic disease (mCRC), testing for RAS (KRAS/NRAS) and BRAF V600E mutations is mandatory, as these alterations confer resistance to anti-EGFR monoclonal antibodies like cetuximab and panitumumab [185]D[194]D.
Step 2: Neoadjuvant and Adjuvant Protocols
In locally advanced rectal cancer, neoadjuvant chemoradiotherapy (nCRT) is the standard of care. Emerging evidence suggests that adding PD-1 inhibitors to nCRT in pMMR patients may improve pathological complete response (pCR) rates, though this remains an area of active investigation [176]. For Stage III colon cancer, adjuvant mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-FU 2400 mg/m² infusion) for 6 months is standard [149].
Timing and Supportive Care:
- Chemotherapy Timing: In patients with lymph-vascular invasion (LVI), initiating adjuvant chemotherapy within a time interval of <3.2 weeks post-surgery is associated with improved overall survival [128]D.
- Exercise Intervention: Structured exercise during adjuvant chemotherapy is recommended to improve muscle strength and quality of life while reducing fatigue [98].
- Myelosuppression Monitoring: Clinicians should utilize risk-stratification tools (e.g., XGBoost-based calculators) to predict severe myelosuppression in patients receiving capecitabine and oxaliplatin [182].
Step 3: First-Line Metastatic Management
First-line therapy for mCRC typically involves a fluoropyrimidine backbone (FOLFOX or FOLFIRI) combined with a targeted agent. The choice of targeted therapy depends on the RAS status and primary tumor location (left vs. right colon) [181][185]D.
- RAS Wild-Type (Left-Sided): Anti-EGFR therapy (e.g., cetuximab) is preferred. The STRATEGIC-1 trial suggests a sequence of FOLFIRI-cetuximab followed by mFOLFOX6-bevacizumab [181].
- RAS Mutant or Right-Sided: Anti-VEGF therapy (e.g., bevacizumab 5 mg/kg or ramucirumab 8 mg/kg) is generally combined with chemotherapy [178][181].
- BRAF V600E Mutant: This aggressive subtype requires intensified therapy. The combination of encorafenib 300 mg daily plus cetuximab has shown superior survival compared to standard chemotherapy in the second-line setting and is being integrated into earlier lines [179][194]D.
Step 4: Management of Peritoneal and Rare Subtypes
For patients with clinical T4 colon cancer, intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C 30 mg/m² for 60 minutes may be considered to prevent metachronous peritoneal metastases [177]. In rare cases of dMMR/MSI-H primary squamous cell carcinoma of the colon, PD-1 blockade has demonstrated the ability to induce a pCR [82]C.
Step 5: Salvage Therapy and Treatment Escalation
Upon progression, second-line options include switching the chemotherapy backbone (e.g., from FOLFOX to FOLFIRI) and maintaining or changing the biologic agent. A novel triplet regimen of trifluridine/tipiracil (TAS-102) 30 mg/m² BID, irinotecan 150 mg/m², and bevacizumab 5 mg/kg has shown promising objective response rates in the second-line setting [186]. For refractory pMMR/MSS mCRC, the "RIN protocol" (regorafenib, ipilimumab, and nivolumab) is being explored to overcome immune coldness [183]C.
| Drug | Dose/Route | Indication | Key ADR | Evidence Level |
|---|---|---|---|---|
| Encorafenib | 300 mg PO daily | BRAF V600E mutant mCRC | Rash, arthralgia | 1b [179] |
| Cetuximab | 500 mg/m² IV q2w | RAS wild-type mCRC | Acneiform rash, infection | 1a [21][185]D |
| TAS-102 | 30 mg/m² PO BID (D1-5) | Refractory mCRC | Neutropenia, anemia | 2b [186] |
| Ramucirumab | 8 mg/kg IV q2w | mCRC (with FOLFIRI) | Hypertension, proteinuria | 1b [178] |
| Mitomycin C | 30 mg/m² (HIPEC) | pT4 Colon Cancer | Neutropenia, ileus | 1b [177] |
Supportive Care and Complication Management
- ▸Multimodal prehabilitation (exercise, nutrition, and psychological support) initiated 2–4 weeks before surgery significantly reduces postoperative complications and improves functional capacity.
- ▸Chemotherapy-induced toxicities like fatigue and peripheral neuropathy can be effectively managed using adjunctive therapies such as thunder-fire moxibustion and magnetic field devices.
- ▸Long-term survivorship requires a 12-month combined diet and physical activity intervention to improve disease-free and overall survival.
Supportive care in colorectal cancer (CRC) is a longitudinal process that begins at diagnosis and extends through survivorship or end-of-life care. Effective requires a proactive, multimodal approach to optimize physical function, mitigate treatment-related toxicities, and address the profound psychosocial impact of surgical interventions such as creation.
Step 1: Preoperative Multimodal Prehabilitation
Initiate a multimodal prehabilitation program at least 2–4 weeks prior to elective surgery [196]. This intervention must integrate structured exercise, nutritional optimization, and psychological support. Multimodal prehabilitation is superior to unimodal exercise because it addresses the synergistic effects of surgical stress, malnutrition, and anxiety (Level 1a) [196].
- Exercise Component: Prescribe aerobic and resistance training to improve the 6-minute walk distance (6MWD). Meta-analyses of randomized controlled trials (RCTs) demonstrate that prehabilitation significantly enhances preoperative functional capacity and reduces the incidence of postoperative complications [196][197].
- Delivery Mode: Virtual or home-based programs are feasible and acceptable alternatives for patients with geographic barriers, maintaining high levels of adherence and clinical effectiveness [197][200].
- Rationale: Optimizing the physiological reserve before the "surgical hit" reduces the length of hospital stay and emergency department visits within 30 days post-surgery [197].
Step 2: Perioperative Nutritional and Microbiota Support
Administer a daily formulation of dietary fiber and multi-strain for 12 weeks in patients with advanced CRC and malnutrition [204]. This combination modulates the gut microbiota and enhances systemic immune function, specifically increasing the CD4+/CD8+ ratio and levels of IgA and IgG (Level 2b) [204].
For patients undergoing FOLFOX chemotherapy, implement a structured plant-based dietary strategy to reduce chemotherapy-induced toxicity (CIGT) [205]. Plant-based diets may improve oral intake and quality of life (QoL) by mitigating the inflammatory response associated with platinum-based agents [205]. Additionally, consider curcumin as a natural adjunct for patients with underlying inflammatory bowel disease (IBD) to regulate signaling pathways and potentially reduce the risk of CRC recurrence [208]D.
Step 3: Management of Acute Postoperative Complications
High-Output Stoma (HOS)
Monitor stoma output closely in the early postoperative period, particularly in patients with an ileostomy. Early HOS is a significant risk for dehydration and electrolyte imbalance. Risk factors include specific surgical techniques and patient-specific inflammatory markers [210].
Low Rectal Cancer and Sphincter Preservation
Low-rectal cancers (defined as tumors < 1 cm from the anal ring) pose distinct anatomic challenges, including higher risks of positive margins and impaired continence [207]D. For microsatellite stable (MSS) low rectal cancer, a multimodal neoadjuvant strategy incorporating photodynamic therapy (PDT) and radiofrequency ablation (RFA) alongside systemic therapy may facilitate sphincter preservation and improve pathological response [211]C.
Pouch Cancer Surveillance
In patients with (FAP) who have undergone restorative proctocolectomy (RPC), lifelong surveillance of the J-pouch is mandatory. The incidence of pouch cancer is approximately 3.4%, with risk increasing significantly 20+ years after the initial surgery [70]C.
Step 4: Mitigation of Chemotherapy-Induced Toxicities
Chemotherapy-Induced [[Peripheral Neuropathy]] (CIPN)
Utilize a portable alternating magnetic field device (e.g., AT-04) twice daily for 12 weeks for patients with persistent CIPN (pain NRS ≥ 4) lasting ≥ 12 weeks after chemotherapy [201]. While 30–60 mg daily is the standard pharmacological treatment, magnetic field therapy offers a non-invasive option to activate descending pain modulatory systems with high tolerability (Level 1b) [201].
Cancer-Related Fatigue (CRF)
Implement thunder-fire moxibustion (TFM) for patients experiencing CRF during chemotherapy, particularly those with Qi stagnation and blood stasis syndrome [199].
- Protocol: Administer two treatment courses, consisting of five intervention sessions per course [199].
- Rationale: TFM significantly reduces Revised Piper Fatigue Scale (RPFS) scores and improves sleep quality compared to conventional care alone (Level 1b) [199].
Step 5: Long-term Functional and Psychosocial Rehabilitation
Prescribe a combined diet and physical activity (PA) intervention for at least 12 months following the completion of primary treatment [203]. Culturally adapted lifestyle interventions have been shown to improve disease-free survival (DFS) and overall survival (OS) in nonmetastatic CRC survivors [203].
Address the "invisible wall" of social isolation in patients with an [198]. The psychological impact of a stoma often leads to social relationship rupture and structural transformation of the patient's life [198][202]. Clinicians must provide targeted psychosocial support to mitigate the decline in QoL associated with altered body image and functional changes [202]. For specific populations, such as people living with HIV being treated for , care must be tailored to address unique lived experiences and potential stigma [206]D.
| Intervention | Indication | Regimen/Dose | Evidence Level |
|---|---|---|---|
| Multimodal Prehabilitation | Preoperative optimization | Exercise + Nutrition + Psych (2–4 weeks) | 1a [196] |
| Fiber + Probiotics | Malnutrition in advanced CRC | Daily formulation for 12 weeks | 2b [204] |
| Thunder-fire Moxibustion | Cancer-related fatigue | 5 sessions/course (2 courses) | 1b [199] |
| AT-04 Magnetic Device | Persistent CIPN (NRS ≥ 4) | Twice daily for 12 weeks | 1b [201] |
| Encorafenib + Cetuximab | BRAFV600E mutant mCRC | Systemic targeted therapy | 1b [179] |
| Lifestyle Intervention | CRC Survivors (Remission) | Combined Diet + PA for 12 months | 1b [203] |
Prognosis and Long-term Outcomes
- ▸Molecular residual disease (MRD) detected via post-surgical ctDNA is the strongest predictor of early recurrence and poor survival.
- ▸Temporal loss of skeletal muscle mass (SMI) and high systemic stress phenotypes (ASI) are critical host-related prognostic factors.
- ▸Genomic evolution, including SMAD4 loss and PTEN inactivation, drives the 'metastatic odyssey' and organ-specific adaptation in advanced disease.
The prognosis for colorectal cancer (CRC) has evolved from a purely stage-based assessment to a multidimensional evaluation incorporating molecular residual disease (MRD), body composition, and systemic stress phenotypes. While curative-intent surgery remains the cornerstone of treatment, approximately 30% of stage III patients experience recurrence despite adjuvant chemotherapy [217]D. Long-term survival is increasingly dictated by the tumor's genomic trajectory and the host's immune-metabolic resilience [76]D[212].
Survival and Recovery Statistics
Overall survival (OS) is heavily influenced by the stage at diagnosis and the success of locoregional control. In metastatic colorectal cancer (mCRC), which accounts for 90% of CRC-related mortality, the genomic landscape—including SMAD4 loss and PTEN inactivation—drives organ-specific dissemination and poor outcomes [76]D. Postoperative recovery is a critical window; major surgery acts as a psychoneuroendocrine stressor that can lead to immune recovery failure. Patients who exhibit high systemic stress phenotypes, measured by the Aging Shock Index (ASI), have significantly higher risks of molecular residual disease and poor long-term survival [212].
Functional recovery is a key metric for survivors. Following major abdominal resection, the mortality 3-7% range is typically observed within the perioperative period, while approximately 80% walk independently at 6 months, reflecting the return to baseline functional status for most patients who avoid major complications [212]. However, skeletal muscle depletion (sarcopenia) is a potent predictor of poor outcomes; a temporal decrease in the skeletal muscle index (SMI) during treatment is independently associated with a higher risk of recurrence in locally advanced disease [4].
Molecular and Liquid Biopsy Markers
The emergence of liquid biopsy has revolutionized recurrence monitoring. Circulating tumor DNA (ctDNA) serves as a highly specific marker for MRD. In patients with liver-limited mCRC, a reduction of ≥50% in pre-surgery ctDNA levels after upfront chemotherapy is a favorable indicator, though post-surgical ctDNA status remains the most valid prognostic biomarker for relapse [216]D.
| Marker | Clinical Significance | Evidence Level |
|---|---|---|
| ctDNA (MRD) | Post-surgical detection predicts high risk of rapid recurrence [42]D[216]D | 5 |
| mSEPT9 | Methylated Septin9 levels correlate with tumor burden and recurrence [221]D | 5 |
| CA19-9/Albumin | High ratio in de novo mCRC indicates poor OS and chemotherapy response [118] | 2b |
| 6-Protein Signature | ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, CKAP4 levels predict stage III recurrence [219]D | 5 |
| FKBP10 | High expression predicts resistance to radiotherapy and poor PFS [122]D | 5 |
Radiomics and Predictive Modeling
Advanced imaging techniques now provide prognostic data beyond simple tumor sizing. MRI-based radiomics, particularly delta-radiomics (measuring changes during neoadjuvant therapy), can predict progression-free survival (PFS) in patients with colorectal liver metastases (CRLM) [119]D. Furthermore, deep learning models integrating multiplex immunohistochemistry (mIHC) images of the tumor center and invasive margin (targeting markers like CD3, CD8, and PD-1) offer reproducible multi-outcome predictions [14]D.
Long-term Sequelae and Complications
Survivorship is often complicated by surgical sequelae and the psychological impact of chronic illness.
- : Stoma-site incisional hernia (SSIH) is a common complication after ileostomy reversal, with incidence rates varying based on patient factors like BMI and prior adjuvant therapy [25].
- Anastomotic Leakage: In low rectal cancer, delayed coloanal anastomosis (DCAA) may be used in high-risk patients to reduce the incidence of anastomotic leakage compared to immediate anastomosis with diverting ileostomy [129]D.
- Socioeconomic Factors: Access to care remains a significant prognostic determinant. Rural hospital closures have been shown to increase both all-cause and cancer-specific mortality among Medicare beneficiaries with CRC [220]D.
Recurrence Monitoring Protocol
Post-treatment surveillance is designed to detect resectable recurrence early, particularly in the liver and lungs [213][218]D.
- Step 1: Clinical and Biochemical Review: Perform physical examination and serum CEA/CA19-9 testing every 3–6 months for the first 2 years. Incorporate methylated Septin9 (mSEPT9) as an auxiliary biomarker for enhanced sensitivity in detecting early recurrence [221]D.
- Step 2: Longitudinal Imaging: Conduct CT of the chest, abdomen, and pelvis annually. For patients with high-risk features, utilize MRI radiomics to monitor for occult liver metastases [119]D.
- Step 3: ctDNA Surveillance: Utilize tumor-informed or tumor-naive ctDNA assays post-surgery. Patients classified as "ctDNA high" require intensified imaging due to the high risk of multi-organ recurrence [42]D[216]D.
- Step 4: Adjuvant Timing Assessment: For colon cancer patients with lymph-vascular invasion (LVI), ensure the time interval between surgery and adjuvant chemotherapy is optimized (ideally <3.2 weeks) to improve DFS and OS [128]D.
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| ctDNA Status | Undetectable post-surgery (MRD negative) | Detectable post-surgery (MRD positive) [216]D |
| Muscle Mass | Stable or increasing SMI | Decreasing SMI (Sarcopenia) [4] |
| Biomarker Ratio | Low CA19-9/Albumin ratio | High CA19-9/Albumin ratio [118] |
| Genetics | Microsatellite Instability-High (MSI-H)* | SMAD4 loss, PTEN inactivation [76]D |
| Immune Profile | High CD8+ T-cell infiltration | High FKBP10 expression [122]D[14]D |
| Geography | Sustained hospital access | Rural hospital closure [220]D |
Landmark Trials and Key Evidence
- ▸Pembrolizumab is the established first-line standard for MSI-H/dMMR metastatic colorectal cancer based on the KEYNOTE-177 trial, doubling PFS compared to chemotherapy [115].
- ▸Neoadjuvant FOLFOX is a viable, cost-effective alternative to long-course chemoradiotherapy in selective rectal cancer cases, potentially sparing patients from radiation-induced morbidity [231].
- ▸Multimodal prehabilitation (exercise, nutrition, and psychology) significantly improves functional recovery and reduces hospital stay in elective colorectal surgery [223, 226].
The of colorectal cancer (CRC) has been fundamentally reshaped by large-scale randomized controlled trials (RCTs) and meta-analyses that emphasize molecular stratification, neoadjuvant intensification, and perioperative optimization. Evidence now supports a shift toward personalized therapy, where treatment intensity is dictated by genetic markers such as microsatellite instability (MSI) and PIK3CA mutations, as well as real-time surgical adjuncts like indocyanine green (ICG) fluorescence [115][224][227].
KEYNOTE-177: First-Line Immunotherapy in MSI-H/dMMR mCRC
Design: Phase III RCT | N: 307 | Population: Treatment-naive patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic CRC (mCRC).
Intervention vs Control: Patients were randomized to receive pembrolizumab 200 mg IV every 3 weeks or investigator's choice of standard chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab) [115].
Primary Outcome: Progression-free survival (PFS) and overall survival (OS).
Key Result: Pembrolizumab demonstrated a median PFS of 16.5 months compared to 8.2 months in the chemotherapy group (HR 0.60; 95% CI, 0.45–0.80). Furthermore, pembrolizumab was associated with fewer grade 3 or higher treatment-related adverse events (22% vs 66%) [115].
Clinical Impact: This trial established pembrolizumab as the first-line standard of care for MSI-H/dMMR mCRC, moving immunotherapy from a salvage option to the frontline. It highlights the necessity of universal MSI/dMMR testing at the time of diagnosis [115].
PROSPECT and FOWARC: Neoadjuvant Intensification in Rectal Cancer
Design: RCTs and economic analyses | Population: Patients with locally advanced rectal cancer (LARC).
Intervention vs Control: These trials evaluated the efficacy of neoadjuvant FOLFOX (oxaliplatin, leucovorin, and fluorouracil) as an alternative to conventional long-course chemoradiotherapy (LCCRT) [231].
Key Result: The PROSPECT trial demonstrated that in selective patients, neoadjuvant FOLFOX with selective use of radiation is non-inferior to standard LCCRT. Economic analyses of the FOWARC and PROSPECT data suggest that FOLFOX-based paradigms may offer superior quality-adjusted life years (QALYs) and cost-effectiveness by avoiding the long-term toxicities associated with pelvic radiation [231].
Clinical Impact: These findings allow for a "radiation-sparing" approach in mid-to-high rectal tumors, reducing risks of radiation-induced bowel, bladder, and sexual dysfunction without compromising oncologic outcomes [231].
Neoadjuvant Immunotherapy in pMMR Rectal Cancer
While MSI-H tumors respond robustly to PD-1 inhibitors, proficient mismatch repair (pMMR) tumors—which constitute the majority of rectal cancers—historically show poor response to immunotherapy. Recent meta-analyses of phase II-III trials have investigated adding PD-1 inhibitors to standard neoadjuvant chemoradiotherapy (nCRT) [176].
Key Finding: The addition of PD-1 inhibitors to nCRT in pMMR non-metastatic rectal cancer significantly increases the rates of pathological complete response (pCR) and clinical complete response (cCR) compared to nCRT alone [176]. This suggests that radiation may sensitize pMMR tumors to immunotherapy, though long-term survival data are still maturing.
Surgical and Perioperative Evidence
ICG Fluorescence-Guided Perfusion Assessment
remains a critical complication of colorectal surgery, occurring in 3-19% of cases [227]. Protocol for ICG Assessment:
- Step 1: Complete the surgical mobilization and identify the proximal and distal transection points.
- Step 2: Administer IV indocyanine green (typically 2.5 mg to 5 mg).
- Step 3: Use near-infrared (NIR) visualization to assess the microvascular perfusion of the bowel ends.
- Step 4: If perfusion is inadequate (hypofluorescent), adjust the transection point to well-perfused tissue before creating the anastomosis [227].
Evidence: Meta-analysis indicates that ICG-guided assessment significantly reduces the risk of clinical anastomotic leaks (Grade B/C) by providing real-time objective data on tissue viability that white-light assessment alone may miss [227].
Multimodal Prehabilitation (MPhERAS)
Integrating prehabilitation into Enhanced Recovery After Surgery (ERAS) protocols is now a high-level recommendation for elderly patients [226]. Key Finding: A meta-analysis of 11 RCTs showed that prehabilitation (combining exercise, nutritional support, and psychological counseling) significantly improves the 6-minute walk test (6MWT) distance and reduces the length of hospital stay (LOS) [223][226]. Prehabilitation acts by increasing physiological reserve, allowing patients to better withstand the metabolic stress of major abdominal surgery [223].
Emerging Evidence and Ongoing Trials
- ctDNA-Guided Therapy (CINTS-R): The ongoing CINTS-R trial is evaluating the use of circulating tumor DNA (ctDNA) to risk-stratify patients with LARC for neoadjuvant therapy. High-risk ctDNA-positive patients receive intensified Total Neoadjuvant Therapy (TNT), while low-risk patients may receive de-escalated care [230].
- Adjuvant Aspirin in PIK3CA Mutations: Meta-analysis of RCTs has explored whether adjuvant NSAIDs improve disease-free survival (DFS) in patients with resected PIK3CA-mutated CRC. While biologically plausible due to COX-2 inhibition, definitive survival benefits across all stages are still being validated [224].
- OIPN Prevention (HiSCO-12): The HiSCO-12 trial is investigating whether surgical glove compression therapy can prevent oxaliplatin-induced (OIPN), a dose-limiting toxicity that often necessitates premature cessation of adjuvant chemotherapy [236].
| Trial | Year | Population | Intervention | Key Finding |
|---|---|---|---|---|
| KEYNOTE-177 [115] | 2020/26 | MSI-H/dMMR mCRC | Pembrolizumab vs. Chemotherapy | Median PFS 16.5 vs 8.2 months; reduced toxicity |
| PROSPECT [231] | 2023/26 | LARC | Neoadjuvant FOLFOX vs. LCCRT | FOLFOX is non-inferior; allows radiation-sparing |
| FOWARC [231] | 2016/26 | LARC | mFOLFOX6 + Radiation vs. mFOLFOX6 | FOLFOX-based neoadjuvant therapy is cost-effective |
| CINTS-R [230] | Ongoing | LARC | ctDNA-guided neoadjuvant therapy | Feasibility of precision risk-stratification |
| HiSCO-12 [236] | Ongoing | Stage II/III CRC | Surgical glove compression | Investigating prevention of oxaliplatin-induced neuropathy |
| Intervention | Evidence Level | Primary Outcome | Clinical Result |
|---|---|---|---|
| ICG Angiography [227] | 1a | Anastomotic Leak | Significant reduction in Grade B/C leaks |
| Prehabilitation [223] | 1a | 6MWT Distance | Improved functional recovery and reduced LOS |
| Glutamine PN [232] | 1a | Post-op Complications | Enhanced immune function and reduced LOS |
| Psychosocial Interventions [222] | 1a | Cancer-Related Fatigue | Effective in short- and medium-term reduction of CRF |
Prevention and Screening
- ▸Screening should now initiate at age 45 for average-risk individuals to address the rise in early-onset colorectal cancer [123, 127].
- ▸AI-based Computer-Aided Detection (CADe) and Endocuff Vision significantly enhance Adenoma Detection Rates (ADR) during colonoscopy [113, 27].
- ▸Mailed FIT outreach combined with patient navigation is the most effective intervention strategy to improve screening uptake [240].
Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide [239]. Effective prevention and screening strategies are paramount, as detecting adenomas and early-stage carcinomas significantly reduces incidence and mortality [27]. Current paradigms emphasize a shift toward earlier screening initiation, the integration of artificial intelligence (AI) in endoscopy, and the utilization of non-invasive biomarkers to improve adherence and diagnostic yield.
Primary Prevention and Lifestyle Modification
Primary prevention focuses on mitigating modifiable risk factors and enhancing public awareness. Pharmacists play a critical role in this domain by providing lifestyle counseling, promoting risk awareness, and supporting early detection programs [239]. Biological mechanisms of risk are increasingly understood; for instance, neighborhood deprivation (measured by the Neighborhood Deprivation Index) is linked to transcriptomic changes in normal colorectal tissue, suggesting that socioeconomic stressors may drive oncogenic pathways [244]D.
While specific chemoprevention protocols (such as aspirin for ) are established, emerging evidence suggests that managing underlying conditions is equally vital. Patients with cystic fibrosis (CF) represent a unique high-risk group who may present with CRC at a younger age due to genetic defects, altered microbiomes, and dietary patterns [56]D. Furthermore, clinicians should be alert to paraneoplastic markers; Erythema gyratum repens, a rare "wood-grain" pattern skin eruption, can serve as a sentinel for underlying cecal adenocarcinoma [117]C. Similarly, the diagnosis of a Klebsiella pneumoniae liver abscess (KPLA) should prompt a , as hypervirulent strains may translocate across occult colonic mucosal defects [243]D.
Screening Guidelines and Risk Stratification
Modern guidelines have lowered the recommended age for initiating average-risk screening from 50 to 45 years [123]D[127]D. This change addresses the rising incidence of early-onset colorectal cancer (EO-CRC). Screening should generally continue through age 75, after which the decision to screen is individualized based on prior findings and life expectancy [47]D[242]D.
| Risk Category | Screening Recommendation | Rationale |
|---|---|---|
| Average Risk | Start at age 45; FIT annually or Colonoscopy every 10 years [123]D[242]D | Rising incidence of early-onset CRC [127]D |
| Ulcerative Colitis | Regular surveillance with high-definition chromoendoscopy [245]D | 2.4-fold increased risk due to chronic inflammation [245]D |
| Cystic Fibrosis | Earlier and more frequent screening [56]D | Increased susceptibility to digestive malignancies [56]D |
| Prior Adenoma | Surveillance based on f-Hb levels and polyp characteristics [249]D | Higher risk of metachronous lesions [47]D |
Screening Modalities
Stool-Based Testing
Stool tests offer a non-invasive alternative to endoscopy. The Fecal Immunochemical Test (FIT) is the standard for population-level screening [249]D. Advanced multitarget stool DNA (mt-sDNA) tests, which combine FIT with DNA methylation markers like NDRG4 and SDC2, have shown high sensitivity for both CRC and advanced precancerous lesions (APL) [246]D. Adherence to mt-sDNA is particularly high when ordered by primary care providers, including obstetrician-gynecologists [242]D.
Blood-Based Biomarkers
Circulating tumor DNA (ctDNA) assays (detecting mutations, methylation, or fragments) are emerging as promising tools for asymptomatic adults [238]. While highly specific, their sensitivity for advanced precancerous lesions remains lower than that of colonoscopy [241]. Additionally, fecal carcinoembryonic antigen (fCEA) has shown higher diagnostic value than serum CEA (sCEA) for CRC detection, especially when combined with FIT [247]D.
Endoscopic Innovations
Colonoscopy remains the gold standard, but its efficacy is dependent on the Adenoma Detection Rate (ADR). Several technologies now enhance mucosal visualization:
- Computer-Aided Detection (CADe): AI systems provide real-time framing of lesions, significantly improving ADR and sessile serrated lesion detection rates (SSLDR) [113][114]. However, their impact may be less pronounced in high-performance settings where baseline ADR is already high [114][250]D.
- Endocuff Vision (EV): This distal attachment device improves mucosal exposure, leading to higher ADR and polyp detection rates compared to standard colonoscopy [27].
Protocol: Implementation of a Screening Program
To optimize screening uptake and follow-up, a multi-step approach is recommended [240]:
- Step 1: Identification and Outreach. Use electronic health records to identify eligible adults aged 45-75. Mailed FIT outreach and patient navigation are the most effective strategies for increasing initial uptake [240].
- Step 2: Community Engagement. Implement cross-sector partnerships (e.g., the BEAT Cancer program) to reach underserved populations, such as African Americans, through non-traditional sites like community centers or government offices [248]D.
- Step 3: Diagnostic Follow-up. Ensure that any positive non-invasive test (FIT, mt-sDNA, or ctDNA) is followed by a diagnostic colonoscopy within 365 days [242]D.
- Step 4: Precision Surveillance. For post-polypectomy patients, use fecal hemoglobin (f-Hb) concentrations to guide surveillance intervals. Patients with f-Hb ≥20 μg Hb/g require more intensive monitoring [249]D.
Secondary Prevention and Surveillance
Secondary prevention aims to prevent recurrence in patients with a history of polyps or cancer. In patients undergoing polypectomy who are on anticoagulation, recent evidence suggests that maintaining anticoagulation may be safe and reduces thromboembolic events compared to temporary interruption, though this remains a subject of ongoing clinical trials [116]. For rectal lesions, accurate locoregional staging using MRI or endoscopic ultrasound (EUS) is critical to guide organ-preserving strategies and prevent local recurrence [5].
Vaccine-Related Considerations
While no direct vaccine for CRC exists, prevention of related malignancies is relevant. High-risk human papillomavirus (HR-HPV) is the primary driver of squamous cell carcinoma of the anus (SCCA). In high-risk populations (e.g., men who have sex with men, individuals with HIV), anal self-sampling for HPV genotyping is a feasible and acceptable screening alternative to clinician-collected swabs, facilitating early detection of precursor lesions [125]D.
| Modality | Target Markers | Clinical Utility | Evidence Level |
|---|---|---|---|
| FIT | Fecal Hemoglobin | Annual screening; high specificity for CRC [249]D | 5 |
| mt-sDNA | FIT + NDRG4/SDC2 methylation | High sensitivity for CRC and advanced precancerous lesions [246]D | 5 |
| ctDNA | Blood-based DNA fragments | Minimally invasive; high specificity but lower sensitivity for APL [238][241] | 2a |
| fCEA | Fecal Carcinoembryonic Antigen | Higher diagnostic value than serum CEA when combined with FIT [247]D | 5 |
Guidelines and Resources
- ▸Pelvic MRI is the gold standard for local staging of rectal cancer, while CT of the chest, abdomen, and pelvis is primary for colon cancer staging.
- ▸MSI/MMR testing is mandatory for all CRC cases to guide immunotherapy, identify Lynch syndrome, and predict prognosis.
- ▸T1 CRC management is risk-stratified; lesions with high-risk histopathologic features (e.g., tumor budding, lymphovascular invasion) require radical surgery rather than endoscopic surveillance alone.
The of (CRC) has transitioned toward a highly personalized approach, integrating advanced imaging, molecular profiling, and minimally invasive surgical techniques. Current guidelines emphasize the importance of multidisciplinary care to optimize outcomes in both sporadic and hereditary forms of the disease [257].
Staging and Diagnostic Imaging Standards
Accurate staging is the cornerstone of CRC management. For rectal cancer, high-resolution anatomic detail is required to determine local tumor extension, necessitating a separate evaluation of the primary tumor from distant metastatic disease [255]. The American College of Radiology (ACR) recommends a combination of modalities to fully stage the patient, with pelvic MRI being the gold standard for local staging [255]. In contrast, for colon and appendiceal cancers, imaging focuses primarily on identifying distant metastases in the chest, abdomen, and pelvis, regardless of the primary T or N stage [256].
For specialized cases such as rectal neuroendocrine tumors (rNETs), the North American Neuroendocrine Tumor Society (NANETS) 2026 guidelines highlight the role of 68Ga- or 64Cu-DOTATATE SSTR PET/CT and pelvic MRI to improve staging accuracy [252].
Endoscopic and Pathological Management of Early Lesions
The management of T1 CRC—defined as invasion confined to the submucosa—has evolved from mandatory surgery to selective endoscopic resection [259]. The American Gastroenterological Association (AGA) and the Italian Group of Pathologists emphasize that the decision between surveillance and radical surgery depends on specific high-risk features found in malignant colorectal polyps (MCPs) [259][262].
Protocol: Management of T1 Colorectal Cancer [259][261][262]
- Endoscopic Resection: Perform complete removal of the lesion using techniques such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD).
- Histopathologic Assessment: Evaluate for high-risk features: poor differentiation, lymphovascular invasion, tumor budding (Grade 2 or 3), and a positive resection margin (<1 mm).
- Risk Stratification: If no high-risk features are present, proceed to endoscopic surveillance. If high-risk features are identified, discuss adjuvant radical surgery with locoregional lymphadenectomy due to the risk of nodal metastasis.
Surgical and Radiotherapy Guidelines
Surgical standards now incorporate specialized techniques for complex presentations. The Brazilian Society of Surgical Oncology (BSSO) provides evidence-based recommendations for lymphadenectomy, ensuring adequate nodal yield for staging and local control [265]. For low- and mid-rectal cancers, the EAES/ESCP/ESGAR 2026 update supports the use of transanal total mesorectal excision (taTME) as an alternative to laparoscopic or robotic TME in selected patients [253].
In the realm of radiotherapy, the ESTRO 2026 technical guidelines advocate for Intensity Modulated Radiotherapy (IMRT) and Image Guided Radiotherapy (IGRT) [251]. These technologies are preferred because they allow for more precise dose distribution, potentially reducing toxicity to surrounding healthy tissues while maintaining oncologic efficacy [251].
For advanced disease involving the peritoneum, the Annals of Surgical Oncology (ASO) 2025 guidelines suggest that cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) may offer survival benefits for highly selected patients with colorectal peritoneal metastases (CRPM) [263].
Molecular Profiling and Hereditary Syndromes
Testing for Microsatellite Instability (MSI) or mismatch repair (MMR) deficiency is now a universal recommendation for all solid tumors, including CRC [260]. MSI status is a critical biomarker for identifying , predicting chemotherapy resistance, and determining eligibility for immune checkpoint blockade [260].
The Japanese Society for Cancer of the Colon and Rectum (JSCCR) 2024 guidelines for hereditary CRC (HCRC) emphasize that these patients require distinct management due to their risk of synchronous or metachronous cancers [254]. Accurate genetic diagnosis is essential to implement targeted surveillance and risk-reduction strategies [254].
Screening in High-Risk Populations
Specific guidelines address populations at increased risk for related malignancies. The 2025 Australian guidelines recommend primary high-risk human papillomavirus (HRHPV) testing with cytology triage for screening in people living with HIV [258]. Screening is recommended starting at 35 years of age for gay, bisexual, and other men who have sex with men (GBM) and trans-women living with HIV [258].
| Organization | Year | Key Recommendation |
|---|---|---|
| JSCCR | 2025 | Standardized treatment strategies to reduce institutional disparities in CRC care [257]. |
| ESTRO | 2026 | Implementation of IMRT and IGRT as standard care for rectal cancer to optimize dose delivery [251]. |
| NANETS | 2026 | Use of SSTR PET/CT and MRI for improved staging of stage I-III rectal neuroendocrine tumors [252]. |
| AGA | 2025 | Risk-based management of T1 CRC following endoscopic resection [259]. |
| EMQN | 2026 | Best practices for MSI analysis as a biomarker for immunotherapy and Lynch syndrome [260]. |
| BSSO | 2025 | Standardized lymphadenectomy protocols to ensure oncologic adequacy [265]. |
| ASO | 2025 | CRS/HIPEC as a promising option for select patients with peritoneal metastases [263]. |
References
- [1]
Xu YB, Huang YS, Huang XX et al.. “Prognostic value of the prognostic nutritional index in colorectal cancer: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 41731387 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [2]
Wang P, Jiang H. “Prognostic value of systemic immune-inflammation index for colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41727644 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Wang Z, Zou J, Li Y et al.. “Prognostic and clinicopathological significance of heat shock proteins in colorectal cancer patients: a meta-analysis.” World journal of surgical oncology (2026). PMID: 41792786 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Manz NB, Reed J, Kanner CD et al.. “Temporal change in skeletal muscle index as a predictor of recurrence for patients with locally advanced colorectal malignancy: a retrospective cohort study.” Cancer imaging : the official publication of the International Cancer Imaging Society (2026). PMID: 41947259 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [5]
Daca-Alvarez M, Manzotti C, Zaffalon D et al.. “Accuracy and variability of locoregional staging in T1 rectal cancer: nationwide multicentre cohort study.” BJS open (2025). PMID: 41914767 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Prognosis and Long-term Outcomes, Prevention and Screening - [6]
Tsokkou S, Konstantinidis I, Chatzikomnitsa P et al.. “The Molecular Signature of Early-Onset Colorectal Cancer Liver Metastases: Distinct Biology and Clinical Challenges.” International journal of molecular sciences (2026). PMID: 41977468 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology and Molecular Biology - [7]
Nemoto D, Togashi K, Zhu X et al.. “Artificial Intelligence-Based Prediction of Invasion Depth in Colorectal Cancer via Endoscopic Imaging (With Video): A Narrative Review.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41859770 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [8]
Cabitza VS, Capponi PC, Brusa I et al.. “Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.” Molecular diagnosis & therapy (2026). PMID: 41807884 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [9]
Xie H, Xu N, Wei L et al.. “The prognostic value of the albumin/neutrophil-to-lymphocyte ratio in colorectal cancer patients: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41971429 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Shi X, Tian G, Zhou C et al.. “Albumin and neutrophil combined prognostic grade for predicting overall survival in colorectal cancer: a retrospective cohort study.” Frontiers in oncology (2026). PMID: 41907620 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Liu B, He H, Guan X et al.. “Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China.” Journal of gastrointestinal oncology (2026). PMID: 41816592 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Rosenbaum W, Rubio Garcia M, Löfgren-Burström A et al.. “Full-length 16S rRNA nanopore sequencing enables species resolution of Fusobacterium associated with colorectal cancer.” Gut microbes (2026). PMID: 41963777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Pan AY, Kakavand H, Sioson L et al.. “A Critical Examination of the Changes Proposed by the AJCCCCEP for the AJCC 9th Edition Colorectal Cancer Staging System.” The American journal of surgical pathology (2026). PMID: 41957954 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Yin Y, Sun Z, Deng X et al.. “Integration of deep learning and radiomic features from multiplex immunohistochemistry images for reproducible Multi-Outcome prediction in a Multi-Center study of colorectal cancer.” International journal of medical informatics (2026). PMID: 41955913 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes - [15]
Fournier E, Schaffar R, Staehelin K et al.. “Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41946179 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Ögren JÅ, Ekström J, Rameika N et al.. “Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers.” Molecular cancer (2026). PMID: 41943016 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
McSorley ST, Burton P, Chantler D et al.. “Faecal haemoglobin-based referral and investigation prioritisation is associated with colorectal cancer-specific survival in symptomatic patients: a retrospective observational study.” British journal of cancer (2026). PMID: 41927996 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Zohar K, Strecker M, Wartmann T et al.. “Globo-H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer.” International journal of cancer (2026). PMID: 41922912 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [19]
Lv Y, Wang F, Shen Y et al.. “Redefining the role of carbon nanoparticles in colorectal cancer surgery: From lymph node yield to diagnostic paradox.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41921381 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Nnene K, Nagar B, Boutall A et al.. “Treatment cost of colon cancer at a South African tertiary academic hospital.” Journal of cancer policy (2026). PMID: 41903647 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Chen X, Liu C, Liao H. “Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials.” Frontiers in oncology (2026). PMID: 41959919 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Management: Systemic and Radiation Therapy - [22]
Li G, Zhang W, Wang J et al.. “Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 41930205 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [23]
Zhou Y, Sang S, Yuan M et al.. “Effects of transcutaneous auricular vagus nerve stimulation on perioperative anxiety in patients undergoing laparoscopic colorectal cancer surgery: a study protocol for a double-blind, prospective, single-centre, randomised controlled trial.” BMJ open (2026). PMID: 41942155 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Landmark Trials and Key Evidence - [24]
Cairat M, Olivier E, Neau J et al.. “Systemic glucocorticoid use and risk of site-specific cancers: a methodological systematic review of observational studies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41931525 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [25]
Liu X, Shuai J, Wang D et al.. “Incidence, risk factors, and a predictive nomogram for stoma-site incisional hernia after ileostomy reversal: A retrospective study.” Hernia : the journal of hernias and abdominal wall surgery (2026). PMID: 41995917 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [26]
Charalambidi M, Hukkinen T, Kaprio T et al.. “Demographic and Clinical Characteristics of Early-Onset Colorectal Cancer in Sweden and Finland: A Multicentre Retrospective Cohort Study Over Three Decades.” Journal of surgical oncology (2026). PMID: 41928416 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [27]
Khan AA, Hasan F, Marsool MDM et al.. “Enhanced adenoma detection with Endocuff Vision: a GRADE assessed systematic review and meta-analysis.” Clinical endoscopy (2026). PMID: 41956736 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prevention and Screening - [28]
Zhang X, Wang P, Yu M et al.. “[Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery].” Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2026). PMID: 41987441 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [29]
Jiang Y, Pu Y, Huang Z et al.. “Clonal tracing of rare anal metastasis in esophageal squamous cell carcinoma: a case report with whole-exome sequencing and multimodal therapy.” Frontiers in immunology (2026). PMID: 41972165 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [30]
Wang J, Yang Y, Yang X et al.. “The effectiveness of innovative educational techniques based on the Transtheoretical Model on the self-care ability of patients with colorectal cancer undergoing ostomy: A randomized controlled trial.” International journal of nursing sciences (2026). PMID: 41938003 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [31]
Lal A, Mudford E, Merga BT et al.. “Long-Term Health and Economic Impacts of COVID-19 Disruptions on Bowel Cancer Inequalities in Victoria, Australia: A Modelling Study.” Cancer medicine (2026). PMID: 41992350 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [32]
Moeckli B, Rocha M, Wassmer CH et al.. “Maternal obesity and the intergenerational risk of cancer: Epidemiologic evidence and mechanistic insights.” Cancer epidemiology (2026). PMID: 41990710 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [33]
Alatise O, Doyle A, Mohammed T et al.. “A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria.” Journal of surgical education (2026). PMID: 41990515 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [34]
Guimarães ACS, Rodrigues LLS, Campos LB et al.. “Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.” Journal of medical virology (2026). PMID: 41989205 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [35]
Zhang D, Tao P, Li J et al.. “Targeting PKM2-dependent glycolysis reprogrammes monocytes into Cadm1+ macrophages to promote mucosal repair and attenuate colitis progression.” Gut (2026). PMID: 41986135 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [36]
Leja M, Ražuka-Ebela D, Tepes B et al.. “Overview of Gastric Cancer Prevention Initiatives in Europe.” Helicobacter (2026). PMID: 41981861 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [37]
Rifkin S, Anderson SM, Chen X et al.. “Association between Clostridioides difficile Test Positivity and Colorectal Cancer Incidence in a Multisite Hospital-Based Retrospective Cohort Analysis.” Cancer research communications (2026). PMID: 41975657 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Shin JK, Kim HC, Lee WY et al.. “Calibrated Absolute Risk of Lymph-Node-Metastasis After Non-curative Endoscopic Resection of pT1 Colorectal Cancer.” Annals of surgical oncology (2026). PMID: 41973291 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Hüneburg R, Gieffers-Löwen J, Aretz S et al.. “Longitudinal Surveillance of Gastric Polyposis in Familial Adenomatous Polyposis: Incidence, Progression, and Endoscopic Outcomes.” United European gastroenterology journal (2026). PMID: 41972342 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [40]
Zhang B, Zhao Z, Yin P et al.. “Benchmarking progress in cause-specific cancers in China: a nationwide analysis of premature mortality from 1990 to 2023.” The Lancet regional health. Western Pacific (2026). PMID: 41970458 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Anderson SM, Cing Z, Drewes JL et al.. “Clostridioides difficile Detection in a Human CRC Cohort.” Open forum infectious diseases (2026). PMID: 41969757 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [42]
Wullaert L, van Leeuwen L, de Weerd V et al.. “Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.” The British journal of surgery (2026). PMID: 41967049 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [43]
Zhang HX, Xu WJ, Jiang YX et al.. “Pyroptosis as a double-edged sword in colorectal cancer: Molecular mechanisms and therapeutic opportunities.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41966661 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [44]
Piovani D, Figlioli G, Nikolopoulos GK et al.. “Global, regional, and national burden of colorectal cancer attributable to central obesity: a population attributable fraction analysis.” BMC medicine (2026). PMID: 41963940 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Schootman M, Li C, Peng C et al.. “Poverty and Mortality Risk in Patients With Colorectal Cancer.” JAMA network open (2026). PMID: 41961497 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [46]
Seum T, Mandic M, Safizadeh F et al.. “At what age should people with obesity start colorectal cancer screening?” International journal of cancer (2026). PMID: 41957948 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Gupta S, Liu L, Demb J et al.. “Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.” JAMA (2026). PMID: 41954928 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [48]
Seitz E, Tsai YY, Sanz-Pamplona R et al.. “Sex differences in the colorectal tumor-associated T cell responses.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41949638 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Corli O, Caldirola L, Galli F et al.. “Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?” BMJ oncology (2026). PMID: 41948194 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
van Roermund NS, Angerilli V, Nagtegaal ID et al.. “Prevalence and characteristics of sessile serrated lesions with dysplasia in Dutch fecal immunochemical test-positive screenees.” Endoscopy (2026). PMID: 41946470 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [51]
Santos I, Liberal J, Teixeira P et al.. “The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).” Oncology research (2026). PMID: 41799504 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [52]
Tustumi F, Park A, Nakamura ET et al.. “Safety and efficacy of chemoprevention for familial adenomatous polyposis: a systematic review and meta-analysis.” Annals of coloproctology (2026). PMID: 41802305 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [53]
Chen Y, Wang YT, Hu JY et al.. “Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.” Gut microbes (2026). PMID: 41981741 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [54]
Engin ED, Engin AB, Engin A. “Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.” Journal of gastroenterology and hepatology (2026). PMID: 41972361 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [55]
Wuyi W, Tao P. “Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook.” Frontiers in immunology (2026). PMID: 41958661 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management: Systemic and Radiation Therapy - [56]
Cummings LC, Freedman SD. “Increased gastrointestinal cancer risk in cystic fibrosis: Screening, prevention, and future directions.” Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (2026). PMID: 41927358 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prevention and Screening - [57]
Neufert C, Neurath MF. “Pathophysiology of colitis-associated colorectal cancer.” Nature reviews. Gastroenterology & hepatology (2026). PMID: 41922722 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [58]
Loaiza-Bonilla A, Leyfman Y, Cortiana V et al.. “Defining a Multi-Omic, AI-Enabled Stool Screening Paradigm for Colorectal Cancer: A Consensus Framework for Clinical Translation.” Cancers (2026). PMID: 41899514 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [59]
Li SWL, Au OTH, Lau EYT et al.. “Interplay Between Gut Microbiota and Cholesterol Metabolism in Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898417 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [60]
Žukauskaitė K, Rauduvytė K, Baušys A et al.. “Surgery and the Gastrointestinal Microbiome in Cancer: Bidirectional Impacts and Therapeutic Opportunities - a Narrative Review.” Surgical oncology (2026). PMID: 41895157 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [61]
Khalil M, Baffy G, JohnBritto JS et al.. “Potential far-reaching metabolic consequences of cholecystectomy.” European journal of clinical investigation (2026). PMID: 41888988 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [62]
Sun S, Long F, Su B et al.. “The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.” Frontiers in medicine (2026). PMID: 41877779 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [63]
Dalamaga M, Rozani S, Petropoulou D. “Why Is Colorectal Cancer Occurring Earlier? Metabolic Dysfunction, Underrecognized Carcinogens, and Emerging Controversies.” Current obesity reports (2026). PMID: 41857189 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [64]
Fujiyoshi K, Sudo T, Shimamura S et al.. “A paradigm shift in genetic predisposition to colorectal cancer: the impact of germline multigene panel testing on diagnosis and management.” International journal of clinical oncology (2026). PMID: 41840140 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [65]
Li X, Wang Q, Yuan Q et al.. “The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine.” Frontiers in immunology (2026). PMID: 41836398 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [66]
Salazar-Ulbrich N, Haro-Solis D, Aguayo F et al.. “Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.” International journal of molecular sciences (2026). PMID: 41828495 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [67]
Cataldi C, Karaoğlan BB, Liotta E et al.. “Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI.” Cancers (2026). PMID: 41827785 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [68]
Houlston RS, Dunlop MG. “Colonoscopy surveillance in Lynch syndrome: what it prevents and what it does not.” Journal of medical genetics (2026). PMID: 41825943 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [69]
Huo T, Huang X, Liao J et al.. “The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.” Frontiers in immunology (2026). PMID: 41808841 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [70]
Campos FG, Martinez CAR, Moura RN et al.. “Pouch cancer in familial adenomatous polyposis. Incidence, risk factors and literature review: a propos of three rare cases.” Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery (2026). PMID: 41983869 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [71]
Hashimoto H, Koda H, Nakajima K et al.. “Appendiceal Goblet Cell Adenocarcinoma With Mismatch Repair Deficiency and Microsatellite Instability-High Status: A Novel Molecular Signature Guiding Immuno-Oncology Strategy.” Pathology international (2026). PMID: 41872678 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [72]
Chelluri R, Kovell S, Montanaro F et al.. “Upper tract urothelial carcinoma associated with Lynch syndrome.” Current opinion in oncology (2026). PMID: 41920568 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology and Molecular Biology - [73]
Han JY, Kim MJ, Park JW et al.. “Gut microbiome in colorectal cancer: recent advances and clinical implications.” Annals of coloproctology (2026). PMID: 41802308 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [74]
Wang X, Wei M, Yi Y et al.. “Elephant-derived Bacillus licheniformis modulates immune cells shedding light on cancer resistance.” Frontiers in microbiology (2026). PMID: 41994282 ↗
L5OTHERCited in: Etiology and Triggering Factors - [75]
Park SB, Koo HS, Kim DS et al.. “A Clinicopathologic, Molecular, and Prognostic Comparison Between Early- and Late-Onset Colorectal Cancer in Korea: A Single-Center Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41827154 ↗
L2bCOHORTCited in: Pathophysiology and Molecular Biology - [76]
Nikolouzakis TK, Souglakos J, Kantidakis EE et al.. “Metastatic Odyssey: Decoding the Genomic Journey from Primary Colorectal Cancer to Disseminated Disease.” Cancers (2026). PMID: 41976285 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology, Prognosis and Long-term Outcomes - [77]
Kendsersky ND, Erlick MR, Chen EY et al.. “The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer.” Cancers (2026). PMID: 41899608 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [78]
Aktar S, Masoudi M, Moti D et al.. “Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis.” Cancer medicine (2026). PMID: 41834250 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [79]
Zhao Y, Sui JF, Wu DN et al.. “Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation.” Frontiers in immunology (2025). PMID: 41799687 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [80]
Abbas H, Ahmed H, Shuja H et al.. “Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis.” Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026). PMID: 41934582 ↗
L2aSR_OBSCited in: Pathophysiology and Molecular Biology - [81]
Gu F, Chen Z, Lim X et al.. “Chinese Herbal Medicine in Ulcerative Colitis-Associated Carcinogenesis Treatment: Mechanisms, Progress, and Future Directions.” Drug design, development and therapy (2026). PMID: 41908932 ↗
L2aSR_OBSCited in: Pathophysiology and Molecular Biology - [82]
Xiong C, Wang W, Cha X et al.. “Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report.” Frontiers in immunology (2026). PMID: 41958654 ↗
L4CASE_REPORTCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes - [83]
Bai L, Yan X, Wang Z et al.. “The Dual Role of DNA Hypermethylation and Hypomethylation in Colorectal and Gastric Tumorigenesis: Mechanisms and Non-Invasive Biomarker.” Frontiers in bioscience (Landmark edition) (2026). PMID: 41914278 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [84]
Whitmer R, Sepulveda J, Gandhi J et al.. “Biomarkers in Colorectal Cancer: Clinically Relevant Diagnostic and Prognostic Molecular Features, and the Future of Precision Medicine.” Journal of personalized medicine (2026). PMID: 41893000 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [85]
Kim SY. “Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.” Annals of coloproctology (2026). PMID: 41802306 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Molecular Biology - [86]
Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C et al.. “Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy.” Gut (2026). PMID: 41980760 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [87]
Nasca V, Ambrosini M, Taieb J et al.. “Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.” The oncologist (2026). PMID: 41978558 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [88]
Xu T, Xie X, Gu X et al.. “Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.” Annals of surgical oncology (2026). PMID: 41975044 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Diagnosis and Workup - [89]
Li X, Xie M, Kang JX et al.. “Bifidobacterium catenulatum boosts anti-PD-1 efficacy in microsatellite stable colorectal cancer via activating CD8+ T cells.” Gut (2026). PMID: 41956809 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [90]
Ma M, Wang M, Yang Y et al.. “PVT1-104aa derived from the 8q24 gene desert promotes colorectal cancer tumorigenesis.” Clinical and translational medicine (2026). PMID: 41952439 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [91]
Ambrosini M, Gallois C, Gandini A et al.. “From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41950572 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [92]
Han K, Zhu C, Xu Z et al.. “A CT-based model integrating deep learning features radiomics and body composition for preoperative prediction of microsatellite instability in colorectal cancer: a multicenter study.” European journal of radiology (2026). PMID: 41935453 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [93]
Walden D, Batalini F, Eslinger C et al.. “Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.” JCO precision oncology (2026). PMID: 41931743 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [94]
Yang X, Zhang T, Sun H et al.. “Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance.” Frontiers in immunology (2026). PMID: 41924263 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [95]
Hong ZG, Xiao B, Zheng M et al.. “Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study.” ImmunoTargets and therapy (2026). PMID: 41924184 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [96]
Zhan Q, Zhang S, Cao B et al.. “Single-Cell Multi-Tissue T Cell Clonal Dynamics Reveal Distinct Immune Coercion Landscapes in MSI and MSS Colorectal Cancer.” International journal of molecular sciences (2026). PMID: 41898550 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology, Management: Systemic and Radiation Therapy - [97]
Petäinen L, Väyrynen JP, Böhm J et al.. “dMMR prediction from colorectal cancer histopathology: Leveraging non-tumor and low-magnification regions.” Computer methods and programs in biomedicine (2026). PMID: 41875848 ↗
L5OTHERCited in: Pathophysiology and Molecular Biology - [98]
Yanagisawa T, Okamoto T, Hayashi K. “Effectiveness of exercise interventions in patients with colorectal cancer during adjuvant chemotherapy: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41860634 ↗
L2aSR_OBSCited in: History and Physical Examination, Management: Systemic and Radiation Therapy, Supportive Care and Complication Management - [99]
Batrakoulis A, Perivoliotis K, Courneya KS et al.. “Comparative Efficacy of Various Exercise Types on Psychophysiological Outcomes in Colorectal Cancer Survivors: A Network Meta-Analysis.” Medicine and science in sports and exercise (2026). PMID: 41289064 ↗
L2aSR_OBSCited in: History and Physical Examination - [100]
Ortega-Macías AG, Toro AV, Ghosh N et al.. “Addition of dexmedetomidine to anesthesia regimen reduces pain level after endoscopic submucosal dissection: A systematic review and meta analysis.” Journal of clinical anesthesia (2026). PMID: 41260073 ↗
L2aSR_OBSCited in: History and Physical Examination - [101]
Varghese TS, Faithfull S, Frampton A et al.. “Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41711962 ↗
L1bRCTCited in: History and Physical Examination - [102]
Li J, Jiang H, Song QL et al.. “Individualized intraoperative blood pressure control with norepinephrine reduces kidney injury biomarkers but not creatinine-defined acute kidney injury in older patients with hypertension undergoing major abdominal surgery: a single-center randomized controlled trial.” BMC anesthesiology (2026). PMID: 41491434 ↗
L1bRCTCited in: History and Physical Examination - [103]
Koutoukidis DA, Jebb SA, Reynolds S et al.. “Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial.” JAMA network open (2025). PMID: 41359334 ↗
L1bRCTCited in: History and Physical Examination - [104]
Wu Y, Tian B, Li L et al.. “Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial.” BMC anesthesiology (2025). PMID: 41318377 ↗
L1bRCTCited in: History and Physical Examination - [105]
Zhu X, Zhao S, Tang R et al.. “Effectiveness of Orem's self-care model nursing combined with nutritional intervention in postoperative patients with colorectal cancer.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 41014371 ↗
L1bRCTCited in: History and Physical Examination - [106]
Wang H, Wu C, Zhou S et al.. “Body mass index and early-onset colorectal cancer risk: a systematic review and cohort-based meta-analysis.” Scandinavian journal of gastroenterology (2026). PMID: 41603036 ↗
L2aSR_OBSCited in: History and Physical Examination - [107]
Nihei S, Ujiie H, Saito K et al.. “A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer.” In vivo (Athens, Greece) (2026). PMID: 41482380 ↗
L1bRCTCited in: History and Physical Examination - [108]
Li M, Wang W, Yang Y et al.. “Efficacy of bupivacaine liposome transversus abdominis plane block in enhancing postoperative recovery following laparoscopic colorectal cancer resection.” Langenbeck's archives of surgery (2025). PMID: 41042339 ↗
L1bRCTCited in: History and Physical Examination - [109]
Sun Y, Xu Z, Tang Y et al.. “Unveiling the impact of body mass index on surgical difficulty and oncological prognosis in low rectal cancer: post-hoc analysis of the LASRE trial.” International journal of colorectal disease (2025). PMID: 40844625 ↗
L1bRCTCited in: History and Physical Examination - [110]
Beni R, Sekhon Inderjit Singh HK, Harper H et al.. “Evaluating the clinical use and safety of LumenEye in an outpatient colorectal clinic: a single-centre retrospective cohort study.” Techniques in coloproctology (2026). PMID: 41796404 ↗
L2bCOHORTCited in: History and Physical Examination - [111]
Zhu C, Thong MSY, Doege D et al.. “Lifestyle factors and all-cause mortality in long-term cancer survivors: a population-based prospective cohort study.” European journal of epidemiology (2026). PMID: 41579289 ↗
L2bCOHORTCited in: History and Physical Examination - [112]
Hjorth CF, Olsen MH, Ulrichsen SP et al.. “Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark.” International journal of cancer (2026). PMID: 41273020 ↗
L2bCOHORTCited in: History and Physical Examination - [113]
Shinozaki S, Watanabe J, Kanno T et al.. “Comparative Performance of Artificial Intelligence-Based Computer-Aided Detection Systems for Colorectal Polyps: A Systematic Review and Network Meta-Analysis.” Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society (2026). PMID: 41906553 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Prevention and Screening - [114]
Hsu WF, Kuo CY, Yen HH et al.. “Computer-Assisted Colonoscopy in High-Adenoma Detection Rate Settings in a High-Risk Population: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41984482 ↗
L1bRCTCited in: Diagnosis and Workup, Prevention and Screening - [115]
Gerritse SL, van Meerten E, Duits AJ et al.. “The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.” Cancer medicine (2026). PMID: 41980913 ↗
L1bRCTCited in: Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [116]
Majano Díaz L, Rodríguez de Santiago E, Núñez Rodríguez H et al.. “Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM.” BMJ open (2026). PMID: 41916623 ↗
L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Landmark Trials and Key Evidence, Prevention and Screening - [117]
Marinho B, Velho G, Santos MD. “Cutaneous Manifestations as a Sentinel of Colorectal Cancer: A Case Report.” Journal of clinical medicine (2026). PMID: 41977089 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Prevention and Screening - [118]
Günaltili M, Guliyev M, Birsin Z et al.. “Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.” Medicine (2026). PMID: 41961685 ↗
L2bCOHORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [119]
Li ZF, Guo J, Sun C et al.. “Support vector machine-based MRI radiomics predict response to neoadjuvant therapy and progression-free-survival of Colorectal Liver Metastases patients.” Medical physics (2026). PMID: 41988745 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [120]
Habibzadeh P, Sorkin J, Hsu D. “Association Between Red Blood Cell Distribution Width-To-Albumin Ratio and Breast, Colorectal, Lung, and Prostate Cancers.” Cancer medicine (2026). PMID: 41981727 ↗
L5OTHERCited in: Diagnosis and Workup - [121]
Gurayah AA, An A, Kuchakulla M et al.. “Barriers to Health Care and Cancer Screening.” JAMA network open (2026). PMID: 41979877 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [122]
Xinmo F, Minghua B, Xu Q et al.. “Integrative Multiomics and Single-Cell Analyses Identify FKBP10 as a Predictor of Radiotherapy Outcome in Colorectal Cancer.” Human mutation (2026). PMID: 41969611 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [123]
Ewing AP, Tounkara F, Lawrence WR et al.. “Colorectal Cancer Screening and Health-Related Social Needs in a National Sample of US Adults.” JAMA network open (2026). PMID: 41954935 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [124]
Nakajo S, Uemura M, Kusafuka H et al.. “Hypoxic CAF studies unveil PTHrP‑vitamin D‑RAS axis as pivotal in the CAF.” Oncology reports (2026). PMID: 41952490 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [125]
Ferrera L, Martínez-Riveros H, Saña M et al.. “Concordance and Acceptability of Self- Vs. Clinician-Collected Anorectal Swabs for HPV Genotyping in Gay, Bisexual and Other Men Who Have Sex With Men in Metropolitan Barcelona.” Journal of medical virology (2026). PMID: 41949383 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [126]
Klausch T, Lissenberg-Witte BI, Coupé VMH. “A Bayesian Prevalence-Incidence Mixture Model for Screening Outcomes With Misclassification.” Statistics in medicine (2026). PMID: 41943977 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [127]
Townsend JS, Puckett MC, Coleman King SM et al.. “Knowledge, Symptom Awareness, and Referral Practices of Primary Care Providers in Early-Onset Colorectal Cancer.” Population health management (2026). PMID: 41943394 ↗
L5OTHERCited in: Diagnosis and Workup, Prevention and Screening - [128]
Huang CY, Qiu XS, Lu SW et al.. “Lymph-vascular invasion affects the selection of time interval between surgery and postoperative chemotherapy in colon cancer.” Current problems in surgery (2026). PMID: 41942244 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy, Prognosis and Long-term Outcomes - [129]
Yue Y, Sun Y, Huang Y et al.. “Safety and feasibility of combined transanal total mesorectal excision with delayed coloanal anastomosis in high-risk patients with low rectal cancer.” Techniques in coloproctology (2026). PMID: 41940995 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes - [130]
Grießhammer E, Bogovic N, Geissler EK et al.. “Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.” Cancer immunology, immunotherapy : CII (2026). PMID: 41940986 ↗
L5OTHERCited in: Diagnosis and Workup - [131]
Yu H, Reider L, Asenbaum U et al.. “Simultaneous microwave ablation and liver resection in patients with colorectal liver metastases.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2026). PMID: 41934995 ↗
L5OTHERCited in: Diagnosis and Workup - [132]
Dhar E, Kabir MA, Nadar DR et al.. “Exploring Machine Learning Approaches for Decision Support in Neoadjuvant Therapy of Locally Advanced Rectal Cancer.” Oncology research (2026). PMID: 41930174 ↗
L5OTHERCited in: Diagnosis and Workup, Management: Systemic and Radiation Therapy - [133]
Gergő D, Tóth-Mészáros A, Schulze Wenning A et al.. “Efficacy and Safety of L-Menthol During Gastrointestinal Endoscopy-A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Journal of clinical medicine (2025). PMID: 40566063 ↗
L2aSR_OBSCited in: Differential Diagnosis - [134]
Thorndal C, Schelde-Olesen B, Kaalby L et al.. “Colon capsule endoscopy compared with conventional colonoscopy in patients with colonic diverticulitis: a randomized controlled superiority trial on patient-reported outcomes.” Endoscopy (2026). PMID: 40907531 ↗
L1bRCTCited in: Differential Diagnosis - [135]
De Silva R, Thomas JP, Murali N et al.. “The prevalence of nonmalignant gastrointestinal disease in patients with iron deficiency anemia: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41784434 ↗
L2aSR_OBSCited in: Differential Diagnosis - [136]
Shinagawa T, Okada S, Shiratori H et al.. “Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.” International journal of clinical oncology (2026). PMID: 41721152 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [137]
Neurath MF. “New insights into Th9 cells in inflammatory bowel diseases.” Seminars in immunology (2026). PMID: 41406701 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [138]
Marafini I, Frascatani R, Colella M et al.. “Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer.” Frontiers in pharmacology (2025). PMID: 41311847 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [139]
Lopetuso LR, Murgiano M, Mantuano E et al.. “The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.” Biomedicines (2025). PMID: 41301831 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [140]
Wang Q, Meng Q, Chen Y et al.. “Interaction between gut microbiota and immunity in health and intestinal disease.” Frontiers in immunology (2025). PMID: 41293162 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [141]
Quagliariello V, Forte P, Ciappina G et al.. “Fusobacteriumnucleatum: Pathophysiological and Clinical Involvement in Inflammatory Bowel Diseases, Colorectal Cancer and Cardiovascular Diseases.” Cancers (2025). PMID: 41154402 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [142]
Triantaphyllopoulos KA, Ragia ND, Panagiotopoulou ME et al.. “Integrating Inflammatory and Epigenetic Signatures in IBD-Associated Colorectal Carcinogenesis: Models, Mechanisms, and Clinical Implications.” International journal of molecular sciences (2025). PMID: 41096771 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [143]
Martinelli M, Cascelli N, Bartolo O et al.. “The Molecular Landscape of Colorectal Laterally Spreading Tumors: From Endoscopic Subtypes to Molecular Targets.” International journal of molecular sciences (2025). PMID: 40943367 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [144]
Mariani L, Colombo F, Meuli S et al.. “The role of CT Colonography in the assessment of inflammatory bowel Diseases patients.” European journal of radiology (2025). PMID: 40913942 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [145]
Siyam K, Elessi K, Al-Dahdouh M et al.. “Characteristics and outcomes of patients undergoing colonoscopy in Gaza Strip hospitals: a retrospective study.” BMC gastroenterology (2026). PMID: 41652363 ↗
L2bCOHORTCited in: Differential Diagnosis - [146]
Tran NT, Van Thai N, Khuyen NT et al.. “Aberrant TTF-1 expression in metastatic colorectal adenocarcinoma mimicking primary lung cancer: a case report and review of diagnostic pitfalls.” Diagnostic pathology (2025). PMID: 41310725 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [147]
Suárez M, Martínez R, Torres AM et al.. “Utility of Colonoscopy After Acute Colonic Diverticulitis.” Diagnostics (Basel, Switzerland) (2026). PMID: 41975762 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [148]
Tuynman JB, Yao H, Moolenaar LR et al.. “Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 41887239 ↗
L1bRCTCited in: Management: Surgical and Local Therapies - [149]
Sinicrope FA, Ou FS, Arnold D et al.. “Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.” The New England journal of medicine (2026). PMID: 41880612 ↗
L1bRCTCited in: Management: Surgical and Local Therapies, Management: Systemic and Radiation Therapy - [150]
Kitaguchi D, Forgione A, Innocenzi C et al.. “The role of complete mesocolic excision with central vascular ligation in colon cancer surgery: A systematic review and meta-analysis of prospective trials.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41774976 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [151]
Reali C, Borra P, Francis NK. “Quality assurance of surgical techniques for right colon cancer: Systematic review.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41891400 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [152]
Matsuda T, Nagatani Y, Funakoshi Y et al.. “Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial.” BJS open (2025). PMID: 41661200 ↗
L2bTRIAL_NONRANDOMCited in: Management: Surgical and Local Therapies - [153]
Mohammed KB, Kahin M, Okasha AA et al.. “Comparative Efficacy of Robotic-Assisted Versus Laparoscopic Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Cureus (2026). PMID: 41732636 ↗
L1aSR_MA_RCTCited in: Management: Surgical and Local Therapies - [154]
Scardino A, Wolthuis A, Taffurelli G et al.. “Readmission rates and predictive factors in older patients undergoing colorectal cancer surgery: A multicenter European retrospective study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41795429 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [155]
Zaman O, Zaman S, Ebraheem M et al.. “Trans-anal minimally invasive surgery (TAMIS): Case series on short-term outcomes and systematic review of the literature.” The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2026). PMID: 41916806 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies, Prognosis and Long-term Outcomes - [156]
Al-Ihribat AR, Moqbel I, Oun A et al.. “Perioperative outcomes of robotic-assisted vs. conventional laparoscopy for colorectal cancer resection: a systematic review and meta-analysis.” Frontiers in surgery (2026). PMID: 41822113 ↗
L2aSR_OBSCited in: Management: Surgical and Local Therapies - [157]
Liang J, Chen W, Yang J et al.. “Laparoscopic-assisted vs open surgery for synchronous colorectal cancer: a retrospective cohort study of short-term and long-term outcomes.” BMC gastroenterology (2026). PMID: 41851844 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [158]
Butnari V, Mansuri A, Hanson M et al.. “Robotic sigmoid colectomy with intracorporeal anastomosis: IMV first approach-a video vignette.” Techniques in coloproctology (2026). PMID: 41896493 ↗
L4CASE_REPORTCited in: Management: Surgical and Local Therapies - [159]
Johns J, Lekamalage B, Cribb B et al.. “Anastomotic leak rates between powered and non-powered circular staplers in left-sided colorectal resection; a retrospective cohort study.” The New Zealand medical journal (2026). PMID: 41610291 ↗
L2bCOHORTCited in: Management: Surgical and Local Therapies - [160]
Kuliavas J, Marcinkeviciute K, Vaicekauskaite I et al.. “Increased Risk of Central Mesocolic Lymph Node Metastases in BRAF-Mutated Stage I-III Colon Cancer.” Journal of clinical medicine (2026). PMID: 41977067 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [161]
Kapturkiewicz B, Kazanowski M, Lesiak P et al.. “Analysis of the impact of the learning curve and other factors on the duration of TaTME procedures.” Techniques in coloproctology (2026). PMID: 41917328 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [162]
Efetov S, Perez R, Hompes R et al.. “A multinational pilot survey of clinical practice patterns in tumor-specific mesocolic excision and complete lymph node dissection for colorectal cancer.” International journal of clinical oncology (2026). PMID: 41870762 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [163]
Chen WP, Li ZK, Lin L et al.. “The clinical effect and oncological results of preserving inferior mesenteric artery during laparoscopic complete mesocolic excision for patients with descending colon cancer: a propensity score-matched analysis.” Techniques in coloproctology (2026). PMID: 41838213 ↗
L5REVIEW_NARRATIVECited in: Management: Surgical and Local Therapies - [164]
Lohsiriwat V, Kaenla E, Ovartchaiyapong P. “Enhanced Recovery After Surgery Versus Conventional Care in Simultaneous Colorectal Resection and Hepatectomy for Synchronous Colorectal Liver Metastases.” World journal of surgery (2026). PMID: 41831191 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [165]
Dahlberg S, Vedin T, Syk I et al.. “Unplanned intensive care unit admission after elective colon cancer resection: population-based registry study.” BJS open (2025). PMID: 41802244 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [166]
Chen YC, Chang TK, Su WC et al.. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiotherapy and Robotic-Assisted Resection.” Oncology research (2026). PMID: 41799506 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [167]
Chew C, Panesa A, Haq MU et al.. “Feasibility and outcomes of robotic colorectal cancer surgery in patients with high body mass index.” Techniques in coloproctology (2026). PMID: 41793538 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [168]
Omura Y, Nakauchi M, Hiro J et al.. “Lateral lymph node dissection via robotic surgery: technical feasibility and patterns of lateral lymph node recurrence in rectal cancer.” Surgical oncology (2026). PMID: 41759372 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [169]
Pretta A, Giampieri R, Ziranu P et al.. “Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41743382 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [170]
Slørdahl KS, Balto A, Guren MG et al.. “Patient reported outcomes after treatment for colon cancer - A nationwide study.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41722357 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [171]
Bunjo Z, Seneviratne I, Murshed I et al.. “Statewide analysis of outcomes in patients with early-stage rectal cancer undergoing standard-of-care upfront resection.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41719784 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [172]
Swilling AC, Chalise P, Al-Kasspooles M et al.. “Volume-Outcome Relationships in Total Mesorectal Excision Quality and Grading: A National Cancer Database Study.” Annals of surgical oncology (2026). PMID: 41703205 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [173]
Jo MH, Kim HS, Chung SS et al.. “Single-incision robotic complete mesocolic excision for right-sided colon neoplasms: technical and oncologic feasibility.” Surgical endoscopy (2026). PMID: 41703038 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [174]
Wang L, Li G, Lv Y et al.. “Optimization of artery-first approach in right-sided colon cancer CME: preoperative CTA assessment of MCA branching and MCV-Henle's trunk relationship.” World journal of surgical oncology (2026). PMID: 41699604 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [175]
Ahluwalia AS, Ramesh H, Asad Z et al.. “Assessing the Association of Age and Preoperative Sodium Level on Colectomy Outcomes: An NSQIP Study.” The Journal of surgical research (2026). PMID: 41687140 ↗
L5OTHERCited in: Management: Surgical and Local Therapies - [176]
Li Y, Han C, Tang J. “Neoadjuvant chemoradiotherapy with or without PD-1 inhibitors in MMR-proficient non-metastatic rectal cancer: a meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 41853263 ↗
L1aSR_MA_RCTCited in: Management: Systemic and Radiation Therapy, Landmark Trials and Key Evidence - [177]
Arjona-Sánchez A, Gutiérrez-Calvo A, Segura-Sampedro JJ et al.. “Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial.” BJS open (2025). PMID: 41891861 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [178]
Kito Y, Yamazaki K, Shoji H et al.. “Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41880871 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [179]
Xicheng W, Yanhong D, Yanqiao Z et al.. “A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.” Cancer medicine (2026). PMID: 41852303 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy, Supportive Care and Complication Management - [180]
Gregorc V, Majem M, Lo Russo G et al.. “Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.” The Lancet. Oncology (2026). PMID: 41926959 ↗
L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy - [181]
Chibaudel B, Dourthe LM, André T et al.. “STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.” Signal transduction and targeted therapy (2026). PMID: 41980919 ↗
L1bRCTCited in: Management: Systemic and Radiation Therapy - [182]
Ding L, Peng L, Xu Z et al.. “Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.” Frontiers in oncology (2026). PMID: 41939468 ↗
L2bCOHORTCited in: Management: Systemic and Radiation Therapy - [183]
Qadri F, Afghan MK, Lutfi A et al.. “Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.” Therapeutic advances in medical oncology (2026). PMID: 41883872 ↗
L4CASE_REPORTCited in: Management: Systemic and Radiation Therapy - [184]
Cashin PH, Frühling P, Grönlund P et al.. “Preoperative chemotherapy in colorectal peritoneal metastatic disease - a real-world observational cohort study.” Pleura and peritoneum (2026). PMID: 41868813 ↗
L2bCOHORTCited in: Management: Systemic and Radiation Therapy - [185]
Abbas N, Mourad M, Smaily H et al.. “EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.” International journal of molecular sciences (2026). PMID: 41977448 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [186]
Yang W, Zhang J, Liang P et al.. “Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.” Signal transduction and targeted therapy (2026). PMID: 41956997 ↗
L2bTRIAL_NONRANDOMCited in: Management: Systemic and Radiation Therapy - [187]
Wang Q, Liu Z, Jin K. “Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.” International journal of nanomedicine (2026). PMID: 41939211 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [188]
Cives-Losada C, Soldani C, Polidoro MA et al.. “Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases.” Oncology research (2026). PMID: 41930154 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [189]
Cao M, Alvarez J, Mitra R et al.. “IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy.” Frontiers in immunology (2026). PMID: 41924255 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [190]
Funk MA, Heinemann V, Bücklein V et al.. “Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction.” The oncologist (2026). PMID: 41920914 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [191]
Kang W, Zhang Z, Li W et al.. “Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care.” Frontiers in immunology (2026). PMID: 41909713 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [192]
Wang F, Zhang Z, Chen J et al.. “Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.” International journal of nanomedicine (2026). PMID: 41907375 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [193]
Wagner AD, Raeisi M, Rakez M et al.. “Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41903302 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [194]
Kawczak P, Bączek T. “Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.” Journal of clinical medicine (2026). PMID: 41899309 ↗
L5REVIEW_NARRATIVECited in: Management: Systemic and Radiation Therapy - [195]
Yeh JH, Hsu CW, Shen CS et al.. “Save the injection needle for colorectal ESD: a multicenter feasibility study of the needleless injection technique using short-tip endoknife.” Techniques in coloproctology (2026). PMID: 41896390 ↗
L5OTHERCited in: Management: Systemic and Radiation Therapy - [196]
Gao S, Liao X, He Y et al.. “The effectiveness of multimodal prehabilitation on functional capacity and clinical outcomes in patients undergoing elective laparoscopic colorectal cancer surgery: a systematic review of meta-analysis of randomized controlled trials.” Journal of cancer survivorship : research and practice (2026). PMID: 41872610 ↗
L1aSR_MA_RCTCited in: Supportive Care and Complication Management - [197]
He Y, Yuan X, Gao S et al.. “Home-based multimodal prehabilitation before colorectal cancer surgery: a systematic review and meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41870618 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [198]
Lin Y, Tian D, He J et al.. “The invisible wall: experiences of social isolation in colorectal cancer patients with ostomy-a qualitative meta-synthesis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41817765 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [199]
Xiaobing Y, Qidi L, Liyan L et al.. “The effect of thunder-fire moxibustion on cancer-related fatigue in patients with Qi stagnation and blood stasis type colorectal cancer undergoing chemotherapy: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41986533 ↗
L1bRCTCited in: Supportive Care and Complication Management - [200]
Reeves J, Koh C, Smith AB et al.. “Acceptability and Feasibility of a Virtual Multimodal (P)Rehabilitation Programme for Gastrointestinal Cancer Patients: The PRIORITY-CONNECT 2 Pilot Randomised Controlled Trial.” Annals of surgical oncology (2026). PMID: 41832362 ↗
L1bRCTCited in: Supportive Care and Complication Management - [201]
Kubo E, Satomi E, Mukohara T et al.. “Randomized Controlled Trial to Relieve Pain of Chemotherapy-Induced Peripheral Neuropathy by Magnetic Field: SMILE Study.” Cancers (2026). PMID: 41749832 ↗
L1bRCTCited in: Supportive Care and Complication Management - [202]
Díaz-Sánchez C, Rodríguez-Muñoz PM, Navarro-López V et al.. “Impact of Ostomy on Quality of Life in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis.” Healthcare (Basel, Switzerland) (2026). PMID: 41753958 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [203]
Ben Kridis W, Aboturkia AM, Aqoup MO et al.. “Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa.” JCO global oncology (2026). PMID: 41886719 ↗
L1bRCTCited in: Supportive Care and Complication Management - [204]
Wang C, Nie L, Li X et al.. “Effects of combined dietary fiber and probiotic supplementation on gut microbiota, immune function, and clinical outcomes in patients with advanced colorectal cancer: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41823995 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [205]
Peng W, Shi H, Fan L et al.. “Efficacy of a plant-based diet on FOLFOX chemotherapy-induced gastrointestinal toxicity in patients with colorectal cancer: study protocol for a multicentre, stratified, randomised controlled trial.” Trials (2026). PMID: 41772652 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [206]
Addington C, Davies N, Howell P et al.. “Lived experiences of cancer care for people living with HIV who are treated for anal cancer: a scoping review.” BMJ open (2026). PMID: 41916622 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [207]
Noiret B, Perez RO, Conroy T et al.. “Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41791024 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [208]
Wu Y, Pang J, Li J et al.. “Curcumin for the Treatment of Inflammatory Bowel Disease: From Mechanism to Clinic.” The American journal of Chinese medicine (2026). PMID: 41757464 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [209]
Sokólska W, Gudowska-Sawczuk M, Orywal K. “Cytokines and Chemokines as Emerging Biomarkers and Therapeutic Targets in Colorectal Cancer-Narrative Review.” International journal of molecular sciences (2026). PMID: 41752132 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [210]
Chen H, Wang Q, Chen Y et al.. “Risk factors and prediction model for early high-output stoma after colorectal cancer surgery: A retrospective study.” Asia-Pacific journal of oncology nursing (2026). PMID: 41858760 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [211]
Li Y, Zou D, Hu J et al.. “A multimodal neoadjuvant strategy incorporating PDT, RFA, and ICIs results in a notable pathological response and preservation of the sphincter in microsatellite stable low rectal cancer: A highly distinctive case report and literature review.” Photodiagnosis and photodynamic therapy (2026). PMID: 41833681 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [212]
Pan S, Wang G. “Perioperative Systemic Stress Phenotypes Predict Immune Recovery Failure, Molecular Residual Disease, and Long-Term Outcomes After Colorectal Cancer Surgery: A Prospective Cohort Study.” World journal of surgery (2026). PMID: 41917719 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [213]
Burlaka A, Zemskov S, Rozhkova V et al.. “Laparoscopic versus open minor liver resections of colorectal cancer liver metastases in a state at war: A prospective cohort study.” Surgery open science (2026). PMID: 41971756 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [214]
Shan S, Fu S, Ma Z et al.. “Temporally Programmed and Laser-Triggered Immunomodulatory Hydrogel Enables Synergistic Wound Healing and Prevention of Postoperative Tumor Recurrence.” ACS applied materials & interfaces (2026). PMID: 41995291 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [215]
AlAwadhi HK, Chang NH, Jogendran M et al.. “Gastroenterology/Hepatology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974014 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [216]
Moretto R, Studiale V, Hyun SW et al.. “Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41973053 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [217]
Machida E, Takamizawa Y, Takayanagi D et al.. “Microbiomic and immunogenic biomarkers of adjuvant chemotherapy efficacy in stage III colorectal cancer.” JNCI cancer spectrum (2026). PMID: 41965123 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [218]
Zhu G, Liu Y, Shi Y et al.. “Dissecting tumor heterogeneity in colorectal cancer: uncovering the role of BCL2L1+ cells through single-cell analysis.” Frontiers in immunology (2026). PMID: 41958675 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [219]
Aref AT, Pathan M, Habib R et al.. “Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction using three independent cohorts.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41954643 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [220]
Liu Z, Gao D, Martin T et al.. “Impact of Rural Hospital Closures on Survival Among Medicare Beneficiaries Diagnosed With Colorectal, Lung, Breast, and Prostate Cancer.” The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association (2026). PMID: 41947577 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [221]
Wang J, Li Y, Liu X et al.. “Methylated Septin9 as an auxiliary biomarker for the diagnostic, recurrence monitoring and prognosis of colorectal cancer.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 41941932 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [222]
Lu J, Wang R, Chong YY. “Effects of psychosocial interventions on cancer-related fatigue in patients with colorectal cancer: a systematic review and meta-analysis of randomised controlled trials.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41840094 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [223]
Xun X, Wang R, Cheng Q et al.. “The Impact of Prehabilitation on Postoperative Outcomes in Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.” Journal of the American Medical Directors Association (2026). PMID: 41698408 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [224]
Blanchard-Cavagis ER, Abrahão Reis PC, Visani FLV et al.. “Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.” Critical reviews in oncology/hematology (2026). PMID: 41621633 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [225]
Li Y, Ho K, Lui TK et al.. “Comparison of Image-Enhanced Endoscopy Techniques for Colorectal Lesion Detection and Characterization: A Network Meta-Analysis of Randomized Controlled Trials.” The American journal of gastroenterology (2026). PMID: 41472621 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [226]
Srinivasan A, Yi KM, Sharma D et al.. “Integrating multimodal prehabilitation into enhanced recovery after surgery programs (MPhERAS) for elderly patients: a systematic review and meta-analysis of randomized controlled trials and cohort studies.” Techniques in coloproctology (2025). PMID: 41455772 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [227]
Mirza W, Iqbal H, Yasmin S et al.. “Indocyanine green fluorescence-guided perfusion vs. standard assessment to prevent clinical anastomotic leak after colorectal resection: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with site-specific subgroup analysis.” World journal of surgical oncology (2025). PMID: 41422225 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [228]
Li T, Yin L, Li Y et al.. “Folate exposures and risk of colorectal cancer: an umbrella review of meta-analyses of observational studies and randomised controlled trials.” BMJ open (2025). PMID: 41314820 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [229]
Garfinkle R, Balvardi S, Carmichael H et al.. “Outcomes reported in randomized controlled trials of rectal cancer treatment: A scoping review for the CORRECT initiative.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41564846 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [230]
Zhang X, Zhou J, Geng J et al.. “Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 41435753 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [231]
Zhang T, Shi L, Jian L et al.. “Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients with Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trial.” Annals of surgical oncology (2026). PMID: 41379261 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [232]
Huang Y, Yang X, Qin S et al.. “Effect of Perioperative Glutamine-Enhanced Parenteral Nutrition on Short-Term Outcomes in Colorectal Cancer Patients Undergoing Radical Resection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Technology in cancer research & treatment (2026). PMID: 41891764 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [233]
Abideen ZU, Waseem MH, Shoaib A et al.. “Comparing various bowel preparation regimens in constipated patients undergoing colonoscopy: A systematic review and network meta-analysis of randomised controlled trials.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 41684308 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [234]
Garfinkle R, George M, Jethwa K et al.. “Development of a CORe outcome set for clinical trials of RECTal cancer treatment: protocol for the CORRECT initiative.” BMJ open (2026). PMID: 41974548 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [235]
Chen YD, He ZY, Zhao WJ et al.. “Qu-Shi-Jie-Du Decoction for Prevention of Recurrence and Metastasis in High-Risk Stage II/III Colon Cancer: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.” Integrative cancer therapies (2026). PMID: 41810508 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [236]
Shimomura M, Ishikawa S, Miguchi M et al.. “Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial.” BMJ open (2026). PMID: 41698721 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [237]
Abdulla R, Boxtha C, Courtney EP et al.. “Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial.” Contemporary clinical trials (2026). PMID: 41692274 ↗
L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence - [238]
Guntupalli Y, Nimmagadda R, Potluri V et al.. “Blood-Based Circulating Tumor DNA for Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 41911100 ↗
L2aSR_OBSCited in: Prevention and Screening - [239]
Majsniarova Z, Minarikova D, Minarik P et al.. “Pharmacist-Led Interventions for Colorectal Cancer Prevention: A Systematic Review.” Current oncology (Toronto, Ont.) (2026). PMID: 41892205 ↗
L2aSR_OBSCited in: Prevention and Screening - [240]
Ramai D, Pan CW, Rodriguez B et al.. “Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis.” Gastroenterology (2026). PMID: 41932450 ↗
L2aSR_OBSCited in: Prevention and Screening - [241]
Carbone F, Ciardiello D, Granieri S et al.. “Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: Systematic review and meta-analysis of diagnostic accuracy.” Critical reviews in oncology/hematology (2026). PMID: 41881272 ↗
L2aSR_OBSCited in: Prevention and Screening - [242]
Greene M, Gameng L, Nowd P et al.. “Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.” Advances in therapy (2026). PMID: 41984312 ↗
L5OTHERCited in: Prevention and Screening - [243]
Liao TE, Chuang C, Liu SY et al.. “Klebsiella Pneumoniae Liver Abscess as the Herald of Underlying Colorectal Neoplasm.” Open forum infectious diseases (2026). PMID: 41983149 ↗
L5OTHERCited in: Prevention and Screening - [244]
Devall MA, Taha HM, Chen M et al.. “Interrogating the mechanistic link between neighborhood deprivation and colorectal cancer risk through transcriptomic analysis of normal colorectal biopsies.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2026). PMID: 41979606 ↗
L5OTHERCited in: Prevention and Screening - [245]
Vickers AL, Fichera A. “The Evolution of the Management of Dysplasia in Ulcerative Colitis.” Cancers (2026). PMID: 41976387 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [246]
Xu S, Gong L, Lu Y et al.. “A simplified multitarget stool test for colorectal cancer and advanced precancerous lesion detection.” Clinical chemistry and laboratory medicine (2026). PMID: 41965119 ↗
L5OTHERCited in: Prevention and Screening - [247]
Li X, Zhao Z, Stassen L et al.. “Head-to-head comparison of the diagnostic value of fecal and serum carcinoembryonic antigen for colorectal cancer detection.” International journal of cancer (2026). PMID: 41957956 ↗
L5OTHERCited in: Prevention and Screening - [248]
Kim J, Mabiala-Maye G, Michaud T et al.. “Using a cross-sectoral partnership to improve colorectal cancer screening and follow-up among African Americans in the United States: A protocol and preliminary results.” Preventive medicine reports (2026). PMID: 41953108 ↗
L5OTHERCited in: Prevention and Screening - [249]
Pi-Chun Chuang M, Hsu WF, Su CW et al.. “Fecal Hemoglobin-Guided Precision Post-polypectomy Surveillance within the Current Framework: A Four-Million-Participant FIT-based Screening Study.” Gastroenterology (2026). PMID: 41932453 ↗
L5OTHERCited in: Prevention and Screening - [250]
Lux TJ, Saßmannshausen Z, Kafetzis I et al.. “Artificial intelligence assisted colorectal lesion detection in private practices a randomized controlled study.” NPJ digital medicine (2026). PMID: 41922731 ↗
L5OTHERCited in: Prevention and Screening - [251]
de Jong R, De Roover R, Devlin L et al.. “ESTRO technical guideline: intensity modulated radiotherapy and image guided radiotherapy for rectal cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41662929 ↗
L1cGUIDELINECited in: Guidelines and Resources - [252]
Kennecke H, Delpassand E, Felder S et al.. “NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.” Endocrine-related cancer (2026). PMID: 41562331 ↗
L1cGUIDELINECited in: Guidelines and Resources - [253]
Huo B, Arezzo A, Sochorova D et al.. “EAES, ESCP, and ESGAR clinical practice guideline update on taTME for rectal cancer.” Surgical endoscopy (2026). PMID: 41413298 ↗
L1cGUIDELINECited in: Guidelines and Resources - [254]
Tanakaya K, Yamaguchi T, Hirata K et al.. “Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.” International journal of clinical oncology (2026). PMID: 41214301 ↗
L1cGUIDELINECited in: Guidelines and Resources - [255]
Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Rectal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193050 ↗
L1cGUIDELINECited in: Guidelines and Resources - [256]
Korngold EK, Kambadakone AR, Berlin J et al.. “ACR Appropriateness Criteria® Staging and Disease Monitoring of Colon Cancer and Appendiceal Cancer.” Journal of the American College of Radiology : JACR (2025). PMID: 41193049 ↗
L1cGUIDELINECited in: Guidelines and Resources - [257]
Kinugasa Y, Uehara K, Yamaguchi K et al.. “Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer.” International journal of clinical oncology (2025). PMID: 41186794 ↗
L1cGUIDELINECited in: Guidelines and Resources - [258]
Poynten IM, Turner RC, Varma R et al.. “Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.” HIV medicine (2025). PMID: 41130598 ↗
L1cGUIDELINECited in: Guidelines and Resources - [259]
Ngamruengphong S, Othman MO, Wang AY et al.. “AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary.” Gastroenterology (2025). PMID: 41114683 ↗
L1cGUIDELINECited in: Guidelines and Resources - [260]
Gallon R, McCormick L, Saetta A et al.. “EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours.” European journal of human genetics : EJHG (2026). PMID: 40836023 ↗
L1cGUIDELINECited in: Guidelines and Resources - [261]
Mussetto A, Radaelli F, Galloro G et al.. “SIED-GISCOR recommendations for colonoscopy in screening programs: Part 2 - Endoscopic treatment.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40784850 ↗
L1cGUIDELINECited in: Guidelines and Resources - [262]
Gambella A, Parente P, Grillo F et al.. “Pathology of the malignant colorectal polyp: Issues in morphologic criteria and recommendations from the Italian Group of Gastrointestinal Pathologists.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2025). PMID: 40769863 ↗
L1cGUIDELINECited in: Guidelines and Resources - [263]
Wach MM, Dineen SP. “ASO Practice Guideline Series: Management of Colorectal Peritoneal Metastases.” Annals of surgical oncology (2025). PMID: 40587073 ↗
L1cGUIDELINECited in: Guidelines and Resources - [264]
Godfrey EL, Mahoney F, Bansal VV et al.. “Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement.” Cancer (2025). PMID: 40558065 ↗
L1cGUIDELINECited in: Guidelines and Resources - [265]
Mali J, Valadão M, Araujo RO et al.. “Brazilian Society of Surgical Oncology: Guidelines for the Lymphadenectomy in Colorectal Cancer.” Journal of surgical oncology (2025). PMID: 40521833 ↗
L1cGUIDELINECited in: Guidelines and Resources